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ABSTRACT
Staphylococcus aureus is an important pathogen causing chronic and invasive
disease worldwide. This bacterium is a leading cause of community and hospital acquired
infections in humans, and is also known to infect wild and domestic animals. Bovine
mastitis, or inflammation of the udder, is one of the most economically relevant diseases
of the dairy industry, with a high incidence worldwide. S. aureus is a major etiological
agent causing this disease. S. aureus mastitis is highly contagious and difficult or
impossible to treat. Management practices at dairy farms, that include good sanitation and
antibiotic use, have been partially successful in reducing the occurrence of this disease,
however, a complete prevention or elimination is still to be achieved. Despite efforts over
more than two decades, an effective vaccine for S. aureus mastitis, that can protect
against heterologous strains of this bacterium, is not yet available. These efforts however,
have improved our understanding of the pathogenicity, virulence factor expression and
immune responses to this bacterium. Studies have indicated that there is significant
intraspecies variability, and an effective vaccine against S. aureus will require the
incorporation of multiple conserved and relevant antigens. Additionally, the route of
vaccine administration and use of adjuvants to aid in antigen delivery and enhancement
of immune responses will also be critical.
S. aureus contains a broad array of virulence factors required for colonization and
disease, including: adhesins, toxins, a polysaccharide capsule, enzymes and immune
evasion molecules, that are required for adhesion, invasion and colonization. Some
viii

virulence factors are highly conserved and centrally important for bacterial survival and
sustenance, making them good vaccine targets. The iron-regulated surface determinant A
(IsdA) and clumping factor A (ClfA) are two such conserved S. aureus extracellularmatrix adhesins that are promising vaccine antigens. However, an effective S. aureus
vaccine for the prevention or reduction of mastitis will need to induce mucosal and
systemic, as well as cellular and humoral, immune responses to these antigens. Bacterial
enterotoxins are well characterized vaccine adjuvants that act by enhancing the mucosal
delivery of antigens and promoting both systemic and mucosal humoral responses.
Cholera toxin (CT), from Vibrio cholerae is a gold-standard vaccine adjuvant that can
promote both humoral and cellular immune responses to co-administered antigens when
delivered to mucosal surfaces.
The work presented here is based upon the overarching hypothesis that a mucosal,
enterotoxin-based vaccine containing multiple relevant antigens will protect cows
against S. aureus mastitis. To construct this vaccine, three immediate aims were
developed. First, to ensure the incorporation of relevant antigens, the variability, genetic
conservation and immunogenicity of the IsdA protein during bovine infection was
determined. Second, a cholera toxin adjuvant based vaccine containing IsdA and a second
antigen, ClfA (IsdA-CTA2/B +ClfA-CTA2/B) was used to vaccinate cows to determine
immunogenicity. Lastly, a new immunoproteomics approach was used to identify
immunogenic antigens for future incorporation into a multivalent vaccine. The results
from these studies, as presented in chapters 2-4, indicate that: 1) the IsdA adhesin is
expressed and conserved in bovine strains of S. aureus, 2) IsdA-CTA2/B + ClfA-CTA2/B
can stimulate significant immune responses in vaccinated animals after intranasal
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administration and 3) immunoproteomics using milk antibodies can be used to identify
new potential S. aureus vaccine antigens. The studies presented here will contribute to
the advancement and understanding of staphylococcal vaccines in general, and
specifically to those that will prevent bovine mastitis.
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CHAPTER ONE: CHARACTERIZATION OF STAPHYLOCOCCUS AUREUS
INFECTION AND ITS PREVENTION BY VACCINE

Background and Introduction
Staphylococcus Aureus “the super bug”
Staphylococcus aureus (S. aureus) is a gram positive pathogen that is known to
colonize almost 30% of the human population, according to the CDC [1]. S. aureus
causes a wide range of clinical disease and life-threatening conditions like pneumonia,
endocarditis, toxic shock syndrome and sepsis [2]. This pathogen has long been
considered a high risk to public health; causing both hospital acquired and community
infections in humans. S. aureus is the fourth most common hospital-acquired pathogen
and the second most common pathogen isolated from surgical sites, causing 9% of
nosocomial infections in United States alone [3,4]. Antibiotic therapy to treat this
pathogen is either ineffective or challenging due to the prominence of antibiotic resistant
strains like MRSA (methicillin-resistant S. aureus) and VRSA (vancomycin-resistant S.
aureus), which are resistant to almost all common use antibiotics [5]. It is estimated that
more than 2 million humans are sickened every year with antibiotic resistant strains of S.
aureus [6]. In 2011, the CDC identified 80,461 cases of severe MRSA infection, which
resulted in 11,285 deaths [7].
In addition to being an important pathogen for humans, S. aureus colonizes and
infects almost all animal species. S. aureus has been reported to cause severe pathologies
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in pets, wildlife and livestock [8,9]. Importantly, S. aureus is known to cause one of the
most prevalent diseases of the dairy industry, called bovine mastitis. Bovine mastitis is
common in all countries worldwide, and is reported to occur in anywhere from 5% to
70% of cows, depending upon herd and location, and in up to 90% of herds [10].
Multiple pathogens can cause bovine mastitis; however, S. aureus caused mastitic
infections are persistent, contagious, and difficult to treat, with low cure rates [11]. S.
aureus mastitis often becomes a chronic and clinical or subclinical inflammatory disease
of the cow udder caused by intra-mammary infection [12]. This is one of most
economically relevant diseases of the dairy industry, causing large economic losses every
year, mainly due to reduced milk yield and quality. While it is difficult to estimate the
losses caused by S. aureus alone, the economic losses caused by bovine mastitis in
general are estimated to be approximately 1.5 billion/year in US, or $100-200/cow [13–
15]. Improved health management practices at dairy farms have decreased levels of S.
aureus infection and disease, however eradication is currently far from achieved.
Attempts to design a vaccine for S. aureus have occurred over decades, however,
an effective vaccine to prevent disease and transmission is still not available for humans
or bovines. Current S. aureus vaccines are either inconsistent or not protective. This is
likely due to the significant intra-species variability of S. aureus and its multitude of
potent virulence factors. The pathogenesis of S. aureus is mediated by this array of
factors, that includes; cell wall proteins, secreted factors, immune evasion molecules and
toxins. These multifunctional proteins and molecules are very important for S. aureus
proliferation and survival inside the host. Many virulence factors play a critical role in
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adhesion, invasion and pathogenesis and hence their presence is highly conserved in
different strains and serotypes.
A vaccine strategy that incorporates conserved virulence factors or cell wall
anchored proteins as antigens will more effectively stimulate cross-protective immune
responses and aid in the eradication of S. aureus disease and colonization. The following
studies focused on developing a cholera toxin adjuvant based vaccine for S. aureus
caused bovine mastitis. Additionally, the identification and characterization of various
virulence factors involved in the infective stage of disease pathogenesis for use as
vaccine targets is described in this work.
Virulence and Pathogenicity of S. aureus
Colonization of S. aureus is a risk factor for invasive disease. Skin and mucosal
surfaces, like the nose, throat, vaginal wall, and gastrointestinal (G.I.) tract, are the
common sites of S. aureus colonization [16]. The squamous epithelium of anterior nares
is transiently colonized in 60%, and permanently in 20%, of the population [17]. One of
the major concerns about nasal colonization is the potential dissemination of the
bacterium to other parts of the body. It has been reported that when nasally colonized
individuals were topically treated for their colonization in the nose, the infection rate of S.
aureus in these individuals to other parts of body was significantly reduced [17].
The S. aureus surface and secreted proteins contribute to an extraordinary arsenal
of virulence factors, promoting survival in extreme conditions within host [10]. These
proteins, that promote colonization to host extracellular matrix (ECM), growth in serum
or tissue, and avoidance of the immune system are important as vaccine antigenic targets
[18]. The majority of these are either secreted from the bacterial cell or anchored to the
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cell wall through sortase action. The expression of these proteins is carefully controlled
by S. aureus to be expressed in response to the challenges encountered in the host for
colonization and survival [19]. Expression is controlled by growth phases, like stationary
or exponential growth, and nutritional conditions, like the limited availability of iron and
other nutrients [20]. Thus the surface of the bacterium plays a critical role in interactions
with the environment and the host [21]. It has been reported that S. aureus can express
up to 24 different cell wall anchored proteins at a given time [22].
Although colonization of S. aureus is associated with increased risk for infection;
the carriers of S. aureus usually exhibit less severe symptoms of disease than typically
seen in non-carriers [17]. This can be explained by the presence of a higher level of antistaphylococcal antibodies in the S. aureus carriers as compared to non-carriers [23].
Carriers have been found to predominantly induce antibodies to adhesive and ECMbinding proteins [24]. Adhesion to the host is a pivotal step in the pathogenesis of S.
aureus, and is a prerequisite for colonization and infection of the host. The wide variety
of proteins and factors that aid in this process are called adhesins. Bacterial adhesins
mediate attachment to ECM, epithelial cells, plasma proteins, endothelial cells and other
microorganisms [25]. Adhesins can be bound on the surface or can be secreted. The S.
aureus Microbial Surface Components Recognizing Adhesive Matrix Molecules
(MSCRAMMs) are the most prevalent group of surface associated adhesive proteins.
Whereas, secreted S. aureus adhesins are commonly referred to as secretable repertoire
adhesive molecules (SERAMs) [26]. MSCRAMMs and SERAMs bind to abundant
ECM molecules like fibronectin (FN), fibrinogen (FG), vitronectin, hemin, bone
sialoprotein, transferrin and collagen [27–34]. Adhesion to mucosal surfaces and
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resistance to innate immunity at this surface is key to pathogenesis, and S. aureus is a
common skin and nasal commensal. Surprisingly, animal S. aureus strains possess very
similar adhesive and immune evasion proteins to human strains, although the targets are
substantially different. Table 1-1 shows S. aureus adhesins and surface proteins that have
been prominently important in causing infection, invasion and colonization in both the
animal and human host [35].
Table 1-1 S. aureus virulence factors involved in adhesion to the host.
Name
Fibronectin binding proteins A, B

Gene
fnbpA, B

Collagen-binding adhesin

cnA

Iron-regulated surface protein A (IsdA)

isdA

Iron-regulated surface protein B (IsdB)

isdB

Iron-regulated surface protein C (IsdC)
Iron-regulated surface protein H (IsdH)
Serin-aspartate repeat proteins C, D and E
Bone sialoprotein-binding protein
Staphylococcal protein A

isdC
isdH
sdrs
bpB
SpA

Extracellular adherence protein

eap/map

Alpha toxin
Transglucosylase IsaA
ESAT-6 secretion system extracellular
protein A
Fe (Ferrous iron transport protein B)
Staphylococcal super antigen-like 5,
11,1 and 7
Capsular polysaccharides
Clumping factor, A

hlA
isaA
esxA

Clumping factor, B

clfB

feoB
Ssl 5,
11,10,7
CPSs
clfA

Function
Adhesins to fibronectin (FN), fibrinogen (FG)
and elastin
Adhesins to collagen (I and IV)
Iron sequestration, cellular hydrophobicity,
resistance to lactoferrin, binds to FN, FG,
haem, hemin, transferrin and fetuin.
Binds to haemoglobin and haem, Iron
sequestration
Binds hemin, haem transport to cytoplasm
Binds hepta-haemoglobin, iron sequestration
Adhesins
Binds bone sialoprotein and FG
Binds Fc domain of Ig, complement factor C3,
Causes degradation of immunoglobulins
MHC-II analog, binds to FN, FG, vitronectin
and collagen, adhesion to host cells, biofilm
formation
Pore forming toxin
Lytic transglucosylase of S. aureus
Involved in abscess formation, virulence factor
and pathogenesis
ferrous iron transmembrane transporter activity
Neutrophil migration, binds to chemokine
receptor, Fc region of IgA.
Alters C3 (CPS5 and 8) or C3b deposition
Adhesion to FG, binds complement factor I
Binds to FG and cytokeratin, skin and nares
colonization
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Cell wall anchored S. aureus proteins possess secretory or sec signal sequence on
the N-terminus and sortase or sorting signal at C-terminus. The sorting signal is
comprised of the LPXTG (Leu-Pro-X-Thr-Gly; X= any amino acid) motif [36]. Cell wall
anchored MSCRAMMs can perform multiple functions, are structurally similar and have
a common mechanism of ligand binding [37]. MSCRAMMs are often the first proteins to
interact with the host, and hence support colonization and immune evasion. S. aureus
possess much genetic plasticity and is involved in horizontal gene transfer, thus different
proteins often perform similar functions, resulting in significant redundancy [38]. This
redundancy is an advantageous adaptation for S. aureus to sustain growth in different
host environments. However, redundancy is a huge disadvantage in determining
functional and physiological roles of these adhesins by mutational study designs.
In addition to adhesion, iron uptake is essential for growth and survival of S.
aureus inside the host. Due to its limited bioavailability, S. aureus has evolved multiple
iron acquisition systems to survive [39]. Iron in animal tissues and serum is sequestered
in the form of transferrin, leaving very low amounts of free iron, approximately to the
order of 10-24 M, which is well below the levels required by bacteria to sustain life [40].
The acquisition of iron in S. aureus is regulated by the Ferric Uptake Regulator (FUR).
The Fur regulator can sense the bioavailability of iron, and act as a repressor to bind and
inhibit the expression of target genes when iron is abundant. However, when iron is
limiting, Fur repression is lifted [41]. Iron regulated surface adhesins (Isd) contain Fur
box sequences upstream of their operon [42]. The Fur regulator is highly conserved in S.
aureus, as well as other bacterial pathogens, and essential for iron sequestration [43].
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The Isd proteins were first identified in 2002, by Mazmanian et al [44]. The series
of Isd surface adhesins and siderophores work in a coordinated manner to transfer haem
from haemoglobin across the membrane and to the cytoplasm. Isd adhesins are known to
have low levels of interstrain variability, potentially due to their critical role in S. aureus
pathogenesis [22]. Four main Isd proteins, out of a total of nine, are anchored to the cell
wall by the cleavage enzymes, sortase A or sortase B. IsdA, IsdB, and IsdH contain
sortase A recognition sequences, which contain a LPXTG motif, and are covalently
attached to the cell wall [45]. IsdC however, has a distinct recognition sequence,
NPQTN, and is anchored to the cell wall by sortase B [30]. All the other Isd proteins
(DEF) are membrane localized in the ABC transporter system [46]. Multiple studies have
proposed the mechanism of iron acquisition by the Isd proteins using haem receptors
[33,34,44,47,48]. Conserved, 125 amino acid long, haem-binding motifs are present in all
Isd proteins that are putative iron transporters [49]. IsdA, IsdB, IsdH, and IsdC contain
these NEAr Iron Transporter (NEAT) motifs. IsdA and IsdC has one NEAT motif, IsdB
has two, and IsdH has three. Iron acquisition through the Isd system starts with the
binding of haemoglobin, myoglobin or hepta-haemoglobin by IsdB and IsdH (Figure 11). IsdB and IsdH can then extract haem and transfer bound haem to either IsdA or IsdE
directly. The transfer of haem however from IsdA is unidirectional through the cell wall
only to IsdC and then IsdE. Haem is further transferred to the bacterial cytoplasm from
IsdE to IsdF, where an ABC permease transfers the molecule across the membrane using
the ATP hydrolyzing ability of IsdD. Haem is degraded to iron by the Fur regulated
cytoplasmic proteins; IsdG and IsdI. Studies reveal that IsdC is essential for this process
and there can be no transfer of haem between IsdA to IsdE [48].
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Figure 1-1. Mechanism of iron sequestration by S. aureus. Depiction of the
mechanism of Isd-mediated iron sequestration by S. aureus. The first two NEAT
domains of IsdH and first NEAT domain of IsdB bind to hepta-haemoglobin and
meth-haemoglobin, which is then transferred to IsdA, and passed in the cell
membrane via IsdC. The bound haem is then moved through the membrane by
IsdDEF, which is then degraded into free iron by IsdG and IsdI. The NEAT domains
of the Isd proteins shown in figure were extracted from the PDB website using the
accession numbers 2H3K, 2MOQ, 2ITE, 2O6P, 2ZDO, 2ZDP [50–53].
In addition to its role in iron-acquisition, IsdA is one of the most wellcharacterized ECM binding adhesins [54]. IsdA has been shown to bind to FN, FG,
transferrin and haem, with higher binding affinity to FN then FG [54]. The affinity of FG
binding to IsdA is in micromolar dissociation constant (Kd) ranges, and 20-fold higher
than that of Clumping factor A (ClfA) [34]. It is known that IsdA can bind to iron bound
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ligands, however, it cannot bind to haemoglobin and hence it is not required for iron
acquisition in the host [29]. IsdA is also reported to promote skin colonization by
increasing the hydrophilicity or negative charge on S. aureus making it less susceptible to
killing by the skin’s natural antimicrobials [54]. Human skin is an effective barrier to
infection, with epithelial cells and cross-linked keratin, and containing antimicrobial
peptides and fatty acids on the surface for defense. In particular, cis-6-hexadecanoic acid
in the sebum of human skin has antimicrobial activity. However, IsdA confers protection
to S. aureus against fatty acid, and enables S. aureus to colonize the skin, by increasing
hydrophobicity, and reducing hydrophobic interactions. Reports suggest that IsdA
mutants are more susceptible to killing by human sebum, and supplementation with IsdA
can fully restore the resistance phenotype [54].
Other S. aureus adhesins have also been well studied. The collagen binding
protein Cna, the FN binding FnBP, and the FG binding ClfA, are cell wall anchored
MSCRAMMs that initiate bacterial adhesion to ECM during intravascular infection.
FnBP contains two very similar groups of proteins called FnbpA and FnbpB encoded by
closely linked genes. In vitro studies suggest the importance of FnBP in adherence of S.
aureus during infection, however, there is contrasting data for the involvement of this
adhesion in endocarditis in rat models [55,56]. ClfA and ClfB are also two closely linked,
but distinct adhesins. ClfA is an MSCRAMM from S. aureus that binds to the C-terminus
of the FG γ-chain [57]. ClfA is also a well-studied virulence factor responsible for
platelet aggregation and clumping of S. aureus in blood plasma and ClfA is a key factor
in a mouse model of septic arthritis and rabbit/rat models of infective endocarditis
[58]. ClfB can also bind to FG and is known to have a prominent role colonization of the
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anterior nares by binding to cytokeratin [29]. The collagen binding Cna adhesin has been
shown to promote adherence of S. aureus to cartilage [59]. The expression of Cna in an S.
aureus cna- mutant increases its virulence [59]. Surface protein A (SpA) can bind to IgG
and IgM antibodies, can inhibit opsonophagocytosis and inflammation, and is also a B
cell super antigen [57]. FN-binding proteins from S. aureus are of particular importance,
as they have the ability to bind to various types of cells in the host and can act as
invasins, forming a bridge between S. aureus and integrin on the surface of nonprofessional phagocytes [60].
Other virulence factors of S. aureus include immune evasion molecules such as:
enterotoxins, inhibitory factors and exopolysaccharides (capsule) [61]. Capsular
serotypes 5 and 8 have been reported to be present in up to 70% of human and ruminant
mastitis isolates, however expression is known to be variable [2]. The ability of the
bacterium to colonize in tissues and disseminate throughout the host is reliant on this
differential expression. Capsule production in S. aureus, as well as the expression of
many other secreted and cell-associated virulence factors are under the control of the
global regulator, accessory gene regulator (agr) [36] Given the importance of these
virulence factors from S. aureus and their conserved nature, there have been many
attempts to design vaccines based upon them. S. aureus adhesins that have been the most
frequently studied as vaccine candidates for humans and animals are described below.
S. aureus Vaccine Antigens and Vaccines
IsdA
As described above, IsdA is an iron-sequestering cell wall anchored protein and
an important ECM adhesin. This protein has been shown to have a critical role in nasal
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colonization mediated by the NEAT domain, and the C-terminal of IsdA is responsible
for cellular hydrophobicity [54,62]. IsdA is an important adhesin for both human and
animal ligands [63]. An investigation of IsdA as a vaccine antigen for humans in
combination with three other surface proteins IsdB, SrdD, and SrdE, was reported using
the murine model. Effective protection was induced by the vaccine when mice were
challenged with S. aureus, and modest opsonophagocytosis reported using serum
antibodies [33]. In 2010, Kim et al., performed a passive immunization study using the
mouse model with IsdA- and IsdB- specific antibodies. Protection against lethal
intravenous S. aureus challenge was reported, and the group concluded that at least
partial protection was achieved due to interference in pathogen’s haem sequestering
mechanism [64]. An immunogenicity trial in mice, conducted in the Tinker lab, was
reported using cholera toxin adjuvant conjugated IsdA (IsdA-CTA2/B). Mice were
mucosally immunized with IsdA-CTA2/B chimera and humoral and cellular immune
responses detected. Results from this study revealed the induction of Th2-type immune
responses that were IsdA specific, showing significant immunogenicity and supporting
the potential of IsdA as a vaccine antigen [65].
ClfA
ClfA is one of the first identified conserved S. aureus adhesins to be considered as
a vaccine candidate alone or in combination with other proteins. This surface protein has
since been extensively studied and validated as a promising vaccine target and has been
licensed by several companies for inclusion into vaccines [66]. In 2001, Josefsson et al.
reported that mice immunized with recombinantly produced ClfA developed less severe
S. aureus arthritis than controls. In addition, passively immunized mice with ClfA
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antibodies showed protection, indicating that protection in active immunization is
antibody (Ig) mediated [56]. Passive immunization with SA-IGIV (Inhibitex, Inc)
polyclonal anti-ClfA antibodies were able to recognize ClfA from S. aureus and inhibit
adherence to FG up to 95% in vitro. SA-IGIV also promoted efficient
opsonophagocytosis in vitro, by opsonizing ClfA coated fluorescent beads, which further
facilitated their phagocytosis by human polymorphonuclear leukocytes. Furthermore, a
combination therapy, using SA-IGIV and vancomycin revealed that the clearance of
bacteremia was significantly higher in combination with SA-IVIG than vancomycin
alone [67,68]. Studies have revealed that there is a requirement of host FG and S. aureus
interaction for establishing septicemia, making ClfA an extremely important vaccine
target [66,69–71]. Despite these many established reports supporting the antigenicity of
ClfA, a contradictory study was recently reported by Li et al.. In this study, the efficacy
of anti-ClfA responses was tested preclinically in rodent and rabbit models.
Immunizations with ClfA induced functional and opsonic antibodies, which were able to
inhibit binding of S. aureus to FG, however only modest reductions in abscess formation
were seen after infection with S. aureus USA 300 [58]. It was also reported that neither
ClfA, nor passively administered ClfA antibodies, could protect against S. aureus
bacteremia or endocarditis in rat models. Furthermore, when mice were challenged with
S. aureus intraperitoneally after immunization with ClfA or ClfA antibodies, slight
increases in bacteremia were observed in experimental murine models as compared to
controls [58]. These contrasting results have been described by others as overly
simplistic, with an improper focus on one antigen [72]. Thus, despite that potential
challenges need to be addressed, ClfA remains a top vaccine candidate for a human
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vaccine, and also for the prevention of veterinary diseases like bovine mastitis. ClfA in
combination with FnbpA was recently incorporated in a DNA/protein based vaccine, that
is reported to induce partial protection of mammary glands in S. aureus mastitis [73,74]
IsdB
IsdB is also a highly conserved cell wall anchored protein from S. aureus that
binds to haemoglobin and aids in iron sequestration. This protein has also been studied
extensively as a vaccine target and is under much scrutiny due to a recent failed human
vaccine trial. In 2006, Kuklin et al., from Merck Research Laboratories, reported a
clinical trial on murine and rhesus macaque models with a vaccine consisting of IsdB +
amorphous aluminum hydroxy phosphate sulfate adjuvant. Results showed up to a fivefold increase in Ig titers after a single dose, and investigators described IsdB as an
excellent S. aureus antigen, with reproducible and significant protection in animal models
of infection [75]. Another report, investigating the role of cellular immunity in IsdBmediated protection in severe combined immunodeficient (SCID) mice, determined the
importance of TH17/IL-17 in IsdB mediated defense [76]. In 2014, A Phase IIB/III
randomized placebo-controlled trial of the Merck V710 (Merck Sharp&Dohme Corp) S.
aureus vaccine comprised of nonadjuvanted IsdB was conducted on 52 patients divided
into 4 groups (2 placebo and 2 vaccinated) prior to elective cardiothoracic surgery.
Reportedly, the vaccine failed to reduce the rate of post-operative S. aureus infections,
and increased the mortality among patients who developed systemic S. aureus disease
[77]. Later the pathophysiology around the results of the failed vaccine trial was
explained as associated with extremely low IL2 levels in deceased patients prior to
vaccination. In addition, the use of a single antigen and a focus on post-operative S.
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aureus infection complicated study results [78]. The explanations regarding this failed
vaccine trial can be due multiple other associated factors, one of them being the
importance of the pre-clinical models used. Mouse immune and cardiovascular systems
respond very differently to vaccines, and to S. aureus infection, than human systems.
Current preclinical research on S. aureus vaccines is thus moving away from the use of
rodents [79].
EsxA
EsxA is a secreted immune evasion protein and virulence factor responsible for S.
aureus abscess formation [22]. EsxA is a part of the S. aureus Ess (ESX secretion)
secretory pathway that contains a cluster of eight
genes: esxA, esaA, essA, essB, esaB, essC, esaC, and esxB [80]. EsxA has been
characterized as a good vaccine antigen, and is included in vaccines alone or in
combination with other antigens. EsxA is known to induce specific antibodies in sera of
multi-drug resistant S. aureus infected patients [81]. In 2015, Bagnoli et al., from
Novartis Research Laboratories reported a clinical trial using a vaccine containing five
antigens (EsxA, EsxB, HlA, FhuD2 and conserved staphylococcal antigen 1A) with
TH1/TH17 adjuvants [82]. The vaccine stimulated functional and opsonophagocytic
antibodies and provided consistent protection in mice challenged with various strains of
S. aureus. EsxA protein was also included in a one dose four component (4C)Staphylococcus vaccine that is reported to induce protection in S. aureus mouse models
through the combined actions of antibodies, CD4+ effector T cells, and IL-17A [83].
Overall the trials and studies on EsxA have shown promising results however, more
exploration is required for its application in human and veterinary vaccines.
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IsdC
IsdC is a member of the Isd family of proteins that aid in transfer of haem across
the cell membrane [30]. It is also a strongly conserved protein that has potential to be
used as a vaccine antigen. IsdC contains one near-iron-transporter (NEAT), domain
similar to IsdA. In S. lugdunensis, it is shown that IsdC is required for biofilm formation
in low iron conditions, for primary cell-to cell attachment and accumulation phase of
biofilm formation [84]. Hence IsdC is an important virulence factor for S. aureus and has
good potential to be used as a vaccine antigen.
Current Vaccines Against S. aureus Human Disease
Currently there is no licensed vaccine for S. aureus human infection. Two
vaccines: StaphVAX (Nabi Biopharmaceuticals) and V710 (Merck Sharp&Dohme Corp)
and 4 passive immunization preparations have completed clinical trials toward FDA
approval. StaphVAX is composed of capsular polysaccharide 5 (CP5) and CP8
conjugated with recombinant exoprotein A (rETA) from Pseudomonas aeruginosa [85].
StaphVAX is reported to have failed in the reduction of S. aureus incidence in
hemodialysis patients [86,87]. V710 provided protection against nasal carriage in a
cotton rat model, increased survival of mice in a sepsis model and induced fivefold
antigen-specific Ig titers [88]. Although in humans, as described above, V710 failed to
reduce the incidence of post-operative S. aureus infection, and increased mortality in the
vaccinated patients who had post-operative S. aureus infections [77]. The development
and licensure of S. aureus human vaccines has been hampered by these two notable
vaccine trial failures. Although there are evidences of single antigen vaccines working in
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humans (Clostridium tetani, Corynebacterium diphtheriae; Tdap), it is widely agreed
upon that the multi-antigen, or multivalent, approach will be essential for S. aureus.
Bovine Mastitis
Bovine mastitis is characterized by acute inflammation of the mammary tissues as
a result of intra-mammary infection. This infection in mammary tissue is most often
established by entry of the pathogen through the teat canal, commonly during the milking
process, and dissemination into the mammary glands [89]. Establishing infection requires
evasion of host innate immune defenses, such as: phagocytosis by neutrophils,
elimination by milking, and the presence of lactoferrin in milk. Inflammation is the
classical clinical sign of bovine mastitis, caused by bacterial proliferation in the
mammary glands and induced by pro-inflammatory cytokines (IL-1β and TNF-α) at the
site of infection [90]. Pathologically, bovine mastitis is defined by elevated somatic cells
counts (SCC), at or greater than 2x105 cell/ml in milk, combined with the presence of the
infecting pathogen [11]. The somatic cells most often seen in mastitis are neutrophils that
have migrated to the mammary glands as a first line of host immune defense [10].
Geographical region contributes to strain specificity for S. aureus bovine disease,
however, one region will have only a few strains causing mastitis [91]. It has been
reported that different quarters of the same udder can be infected with different strains of
S. aureus, mount different levels of immune responses and have different severity of
disease [92]. In addition, there are known risk factors defining the susceptibility of a cow
to mastitis, such as: the stage of lactation, presence of lesions on teat skin, and the breed
of cow [93–96]. The route of transmission is also an important consideration that can
contribute to progressive colonization and severity of infection [97]. It is known that if S.
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aureus contaminates the teat orifice, it multiplies there and enters the teat canal for
progressive colonization and dissemination. This infection occurs mainly by milking
machine, and due to intra-mammary changes in pressure causing the bacterium to be
transferred to the teat sinus [98].
Infection of bovine mastitis can remain in the subclinical, or chronic, phase
indefinitely, or it can alternate between clinical and subclinical disease. The progression
of bovine mastitis is defined by three stages: 1) pathogen invasion, 2) infection and 3)
inflammation [99]. In the invasion stage, the pathogen moves up the teat canal. In the
infective stage, bacteria bind and adhere to mammary cells to establish infection in the
gland cistern, divide and proliferate. In the final inflammatory stage, there is an increase
in SCC, more cytokines are released and clinical signs of disease appear. As shown in
Figure 1-2, the mammary glands of cows are anatomically designed to function as
barriers of inoculation and progression of pathogens. The teat canal of the mammary
gland is an important barrier and first line of defense against intra-mammary infection.
Teat sphincter muscles in the canal keep the canal closed, so that the mammary gland is
isolated from any potential infection of bacteria [100]. However, damage to the teat canal
and teat skin can increase the risk of mammary gland infection. The surface of the teat
canal contains fatty acids and keratin proteins that acts as a bacteriostatic agents [101].
Additionally, cationic proteins present in the teat canal can bind to pathogenic bacteria,
increasing their susceptibility to the osmolarity of the canal [102]. If bacteria penetrate
the teat canal, they encounter the innate and adaptive immune responses, including:
neutrophils, macrophages and lymphocytes [40]. The proinflammatory cytokines TNF-α
and IL-1β are also released at the site of infection, stimulating the bactericidal activity of
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neutrophils and macrophages, which in turn produce leukotrienes and prostaglandins to
increase the local inflammatory reaction [103]. Epithelial cells of the mammary gland
also play an important role in neutrophil recruitment to the infection site, adherence of
bacteria and interaction with bacterial toxins [104]. Thus the innate and adaptive immune
responses perform crucial roles in the pathophysiology of bovine mastitis, and these
responses are regulated mostly by pro-inflammatory cytokines, increases in macrophage
and neutrophil bactericidal activity, recruitment of neutrophils to the site of infection,
and maturation DCs [105].
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Figure 1-2. Inflammatory model of S. aureus caused bovine mastitis. A) The
infective stage of S. aureus transfer through the teat canal and its colonization and
movement through gland cistern and alveolus. B) The inflammatory phase,
highlighting the magnified section of alveolus. The binding to S. aureus to mammary
epithelial cells is shown, in addition to the internalization of S. aureus in macrophages
and neutrophils plus the induction of inflammatory cytokines IL-1β and TNF-α.
Physiological attributes associated with the mammary glands also make them
more susceptible to S. aureus colonization and infection. Despite the high concentration
of iron-binding proteins like lactoferrin, milk is an excellent, nutrient-rich, medium for
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bacterial growth. In addition, the mammary glands of cows have reduced hydrolytic
enzymes and phagocytic activity, to prevent the engulfment of milk components like
proteins and fats [106]. This lack of phagocytosis prevents the engulfment of pathogenic
bacteria as effectively as seen in other tissues of the body. In the absence of a strong
phagocytic response, S. aureus adhesins can bind to the mammary gland epithelium and
macrophages, to induce bacterial uptake and intracellular survival inside these cells
[107]. Casein protein is in abundance in mammary glands due to the prevalence of milk;
this protein can coat the surface of neutrophils disabling their pseudopodia and hence
their ability to translocate [108]. Complement proteins and opsonizing antibodies are low
in abundance in milk and mammary tissues, which also helps bacteria to colonize and
cause infection without stimulation of the complement system or opsonization. Lastly, it
is reported that during the bovine pre-and post-parturition period there is a functional
impairment of lymphocytic and neutrophilic activity due to stress, hormonal changes and
lactation [109].
The pathogenicity of S. aureus in the mammary gland is a combined effect of
virulence factors, specifically the ones that help in adhesion to host tissue, those that
promote tissue damage and those that promote intracellular survival and evasion of host
immune system. The virulence of some strains of S. aureus is dependent on growth phase
and nutrient availability [110]. As described above, S. aureus produces a number of
important proteins that bind to FN, FG and collagen, and these are involved in
colonization of the udder. Lack of the adhesin, FnBP, causes a delay in internalization of
S. aureus in mouse mastitic epithelial cells compared to the wild type [55]. Extracellular
fibronectin binding protein (Efb) is studied for its immunogenicity in subclinical bovine
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mastitis, in combination with FnbpA and ClfA, and shown to stimulate a strong humoral
and mucosal immune response in vaccinated animals [111,112]. Eap/map virulence factor
binds to ICAM-1 located at the surface of endothelial cells and blocks neutrophil binding
to these cells [113]. Other virulence factors that contribute to disease progression and
inflammation during mastitis include: exotoxins, bacterial super antigens, proteases and
anti-phagocytic factors.
The adhesive ECM molecules like FN, collagen, FG, laminin, vitronectin and
elastin are present in the mammary gland and interact with bacterial adhesins, aiding in
adherence and colonization [100]. FN exists in soluble and insoluble forms in the matrix
and serves as a bridge between S. aureus and integrin-β1. This bridge, or contact, of S.
aureus-to cell-to ECM is important to prevent apoptosis. After adhesion is established by
S. aureus to mammary epithelial cells or MacTs, the integrin receptor starts the cascade
of transduction events leading to uptake of bacteria [114,115]. Adherence to FN is
essential S. aureus infection, and it has been demonstrated that using anti-FN antibodies,
can significantly reduce adherence of S. aureus to epithelial cells [116,117]. S. aureus
FN-binding adhesins include FnbpA and IsdA, and these represent good bovine mastitis
vaccine targets.
Treatments and Prevention of Bovine Mastitis
Bovine mastitis results in economic losses to dairy farmers due to poor milk yield,
veterinary expenses, culling and discarded milk [118]. If bulk milk tank SCC is 400,000
cells/ml, or higher, it is considered unfit for human consumption [119]. S. aureus, clinical
or subclinical infection, is a major contributor to high SCC in bovines. Currently bovine
S. aureus is treated with antibiotics, however, the cure rates are variable and often low
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[120]. There are several parameters which determine the success of antibiotic treatment
and cure. These include: higher than average increase in SCC, age of the cow, duration of
infection, quarters of udder infected, resistance of strain, and bacterial load [121]. It is
known that any quarter of the cow udder can be infected with S. aureus, and reports
suggest that hind quarters have higher cure rates than front quarters [122]. Antibiotics
found to deliver higher cure rates include: amoxicillin, erythromycin, cloxacillin, and
pirlimycin [123]. The efficacy of antibiotic therapy for bovine mastitis varies between
4% to 90%, depending upon the causal agent. S. aureus caused mastitis is among the
most difficult to treat, with cure rates lower than 25% [124]. The unique ability of S.
aureus to internalize in mammary gland epithelial cells or neutrophils/ macrophages
affects the efficacy of antibiotics due to restricted access of innate and adaptive immune
cells [125]. Furthermore, S. aureus is known to form biofilms in the udder, which also
contributes to antibiotic resistance [126]. In addition to lower cure rates, there are other
disadvantages of antibiotic use. Overuse or misuse of antibiotics can lead to the
emergence of new antibiotic resistant strains of bacteria, which risks non-treatable
infection, resistant strains in the food chain, and possibly the presence of antibiotic
residues in cow milk. The cost of antibiotics and its long-term use impact animal health,
agricultural economics and public health.
Prevention of S. aureus mastitis with an effective vaccine would be a much
preferable option over treatment. Developing a vaccine has proven to be difficult
however, and those currently available provide limited efficacy and protection. Currently,
there are two bovine S. aureus vaccines: Mastivac I (Ovejero Laboratories) and
Lysigin/Somato-staph (Boehringer Ingelheim Vetmedica, Inc.). Mastivac, is a
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commercially available vaccine, composed of fragments from three bovine clinical
staphylococcal strains (VLVL8407; ZO3984 and BS449). This vaccine’s compositions
are exosecretions of strains VL8407 and bacterial fragments of strains of ZO3984 and
BS449 mixed with either incomplete Freund’s adjuvant (IFA) or ISA (SEPPIC, d’Orsay,
Paris, France) [106,127,128]. Mouse trials using this vaccine did show immunogenic
properties in addition to protection against homologous and heterologous S. aureus
challenge, however, in bovine trials, only a slight reduction in new S. aureus udder
infection was observed [106]. Lysigin (Boehringer Ingelheim Vetmedica, Inc.) is another
commercially available vaccine for bovine mastitis, it is composed of a lysed culture of
antigenic polyvalent somatic antigen containing S. aureus phage types I, II, III, IV and
capsular polysaccharides [129]. This vaccine is capable inducing anti-staphylococcal
antibodies in bovines, however it stimulated insufficient opsonizing antibodies in milk to
facilitate phagocytosis and clearance of S. aureus from the mammary gland [130].
Induction of opsonizing antibodies is an important attribute of an effective S. aureus
vaccine [131].
While current vaccines are reported to reduce the incidence of S. aureus caused
bovine mastitis, they were not capable of complete prevention or elimination of
transmission, and are not commonly used by dairy farmers in the U.S. An effective
vaccine for S. aureus caused bovine mastitis thus still remains a top priority for the dairy
industry. As stated above, the success of an S. aureus vaccine will depend upon the
inclusion of multiple relevant antigens, and importantly, the success of such a vaccine
will also depend upon induction of an effective immune response. For subunit based
vaccines, the use of the correct adjuvant, to aid in proper antigen presentation and
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enhancement of the immune response to make memory responses and induce long term
efficacy, is essential. As described below, cholera toxin (CT) is a unique and promising
vaccine adjuvant that may be effective to prevent bovine mastitis.
Cholera Toxin as an Adjuvant for Subunit Vaccines
Bacterial enterotoxins like: CT, heat labile toxin (LTI, LTIIa, LTIIb) and shiga
toxin (Stx1 and Stx2), have long been studied as vaccine adjuvants. CT is a secreted AB
type enterotoxin from Vibrio cholerae that is responsible for the watery diarrheal clinical
outcome of disease. CT is composed of a larger heteromeric A subunit (240 amino acids;
MW 28 kD) located centrally, and five homomeric B subunits (103 amino acids; MW 11
kD) located peripherally [132]. The A subunit consists of two domains (Al and A2) and
the upper A1 domain is held above the plane of the doughnut-shaped pentameric B
subunits by the tethering A2 domain. The A1 domain is essential for enzymatic activity
and conducts ADP ribosylation within the host cell. The five B subunits act as a receptor
for cell entry by high-affinity binding to GM1 ganglioside present at the cell surface
[133]. GM1 gangliosides are expressed ubiquitously on the surface of antigen presenting
cells (APCs), macrophages, dendritic cells (DCs), natural killer cells (NK cells),
epithelial cells and B cells [134].
V. cholerae colonizes the intestinal epithelium, and once attached, the bacterium
secretes toxin. CT is activated by host proteases (“nicking”) prior to entry into the cell
[135]. As shown in Figure 1-3, once bound to host GM1, CT is transported into the
endosomes, and moved in a retrograde path through the Golgi apparatus to the
Endoplasmic Reticulum. The ER considers CT an incorrectly folded protein and degrades
it using ER associated degradation (ERAD) [136]. Once degradation occurs the A subunit
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crosses the ER membrane into the cytosol. The A1 subunit retains its native state in the
cytosol and enzymatically triggers ADP ribosylation of Gαs. This results in an
irreversible increase in the intracellular concentration of cAMP, activation of PKA
(protein kinase A), and phosphorylation of the cystic fibrosis transmembrane receptor
(CFTR) Cl- channel. The activation of CFTR leads to efflux of chloride ions out of the
cell, causing massive water efflux, and the severe watery diarrhea that is characteristic of
cholera disease [137].
The translocation and stimulatory activities of CT toxin also make it an optimal
vaccine adjuvant, especially for an intracellular and mucosal pathogen like S. aureus
[138]. CT is immunogenic and is known to stimulate systemic and mucosal humoral and
cellular responses [139]. CT can also potentiate the immunogenicity of most antigens,
whether these are linked to or simply admixed with the toxin, provided that the antigen is
given at the same time and at the same mucosal surface as the toxin [140]. Specifically,
CT has been reported to induce: (i) the activation and permeability of the intestinal
epithelium, leading to higher antigen uptake, (ii) increased antigen presentation by
antigen presenting cells (APCs), (iii) the promotion of isotype differentiation of B cells to
induce secretory IgA production, (iv) the promotion of stimulatory and inhibitory effects
on cytokine production and (v) the upregulation of co-stimulatory molecules, such as
MHC class II, to promote T cell differentiation.
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Figure 1-3. Model of CT entry and trafficking. CT binds to the B subunit by GM1
gangliosides. It then traffics through the early endosome to the Golgi apparatus and
is eventually delivered to endoplasmic reticulum (ER). Once in ER the A1 subunit is
unfolded and retro translocated by the ERAD pathway to the cytosol. Once in
cytoplasm A1 subunit refolds into native form and activates adenyl cyclase and the
increase in cAMP causes chloride secretion.
Native Ct: Immunostimulatory Effects
Induction and potentiation of APCs is one of the most important characteristics of
an adjuvant [141]. Native, toxigenic CT has been shown to play a role in the maturation
and induction of DCs in humans and mice [142]. B cells also play an important role
establishing immunity by the production of antibodies and antigen presentation, it has
been shown that when B cells are treated with CT they increase the induction of co-
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stimulatory signals required for activation of T cells by APCs [143–145]. Antigens
conjugated to CT can be mucosally delivered faster and more efficiently to APCs, and
this includes DCs, macrophages and B cells [140]. The stimulatory effects CT has on
antigen presentation as well as the increase in the activation and migration of DCs
suggests that CT is able to elicit both innate and adaptive immune responses through its
actions on APCs. CT is also known to enhance T cell proliferation by increasing IL-12
and IFN-γ cytokines when coadministered with an antigen [142]. In vitro studies indicate
that a very small amount of antigen is required to stimulate a proliferative T-cell response
when conjugated with CT [146]. Although the polarity of immune responses generated
by CT is a matter of debate, some studies indicate that CT-treated DCs prime the naïve T
cells in vitro and drive them towards a Th2 phenotype. However, a few studies report that
the toxin induces a mixed Th1/Th2 type of immune responses [147].
The success of any vaccine relies on the stimulation of unique antibodies against
the antigen of interest and prevalence of those antibodies as an immunological memory
[148]. B-cell antigen presentation is an important criterion in establishing an effective
immune response with vaccines [149]. Current adjuvants have been chosen and designed
based on their ability to elicit a cellular responses, specifically their abilities to induce a
Th1, Th2, or Th17 cell response, as well as the amount of Ig produced [150]. CT has long
been reported to induce antigen-specific IgG and IgA to co-administered antigens,
however, little information exists regarding the ability of CT to influence immunologic
memory [148]. More recently, Bemark et al., reported the memory-inducing capabilities
of CT on B cells in mice [151]. Another report has indicated that CT supports the
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development of immunologic memory by proliferation and activation of lymphocytes
within the (GCs) germinal centers [152].
Non-Toxic CT Derivatives
While native CT is the gold-standard, non-toxic CT derivatives have also been
found to retain significant adjuvant activity. CT as compared to CTB showed enhanced
antigen-presenting capabilities, suggesting a supportive role of toxicity on antigen
delivery [140]. However, it has been reported that B cells treated with CTB alone
experienced an increase in the co-stimulatory signal required for T-cells activation. A
recent study by Lundgren et al., showed that specific memory IgA antibodies against
CTB were induced in the intestine by the oral CTB-based cholera vaccine, Dukoral
[148]. A non-toxic purified monomeric CTA1-DD (adjuvant) fusion protein, that contains
the ADP-ribosylating enzyme from CT combined with the immunoglobulin binding
domain of Staphylococcus aureus protein A, was shown to directly stimulate mast cells
and to release TNF-α [153]. Mast cells are a promising target for adjuvants as they are
located on the skin and throughout mucosal surfaces and act as a first line defense for
many pathogens. Their location within the mucosal tissue combined with their newly
found role for altering adaptive immune responses make them an interesting target for
adjuvants [154]. This team also found that immunized mice had Ig half-lives that were
two to three times longer than Ig from mice immunized with other adjuvants.
Interestingly, the increase in Ab half-lives correlated with an increase in germinal centers
(GC) activity [151].
While CTB clearly retains significant adjuvanticity, the mechanism of antigen
conjugation or interaction, route of administration, and concentration of antigen/adjuvant
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notably affect the immunstimulatory outcome. It has been reported that CTB directly
conjugated to an antigen and administered orally, nasally or sublingually at high
concentrations, can induce tolerance more than the administration of antigen alone [155].
CTB has also been reported to induce autoimmunity to self-antigens and tolerance to
autoimmune antigens, however, this seeming paradox is not currently well understood
[156,157]. The most recent studies using CTB adjuvant have focused on the ability of
CTB conjugates to act as proinsulin vaccines to suppress diabetes [158,159]. It remains to
be determined if this versatility will be a benefit for the use of CTB-based adjuvants or a
potential disadvantage.
CTA2/B chimeras are toxin-based vaccines plus adjuvant that possess the GM1
binding ability of the B subunit and the ER targeting (KDEL) motifs on the A2 subunit.
These molecular possess the unique adjuvant qualities of CTB and are non-toxic [65].
The CTA2/B holotoxin-like molecule was first constructed in 1992 to develop an
adjuvant that could be linked to the antigen of interest [160]. These molecules have since
been reported as potential vaccines by a number of groups [161–170]. The Tinker
laboratory has reported the construction a and purification of CTA2/B with the LcrV
protective antigen from Yersinia enterocolitica and Y. pestis, making LcrV–CTA2/B
chimeras [168]. This chimera showed the uptake and trafficking of the LcrV antigen like
CTA2/B in vitro, reflecting the antigen-delivery ability of the CTA2/B adjuvant [171].
CTA2/B chimeras have also been used as mucosal adjuvants in a subunit vaccine against
S. aureus. In this report, the Tinker Laboratory developed an IsdA-CTA2/B chimera that
stimulated significant humoral immune responses in mice after intranasal delivery [161] .
Furthermore, a DIII-CTA2/B chimera, targeted against the West Nile Virus, was
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constructed and found to induce antigen-specific IgM and IgA responses in mice [170].
In summary, the current data suggests that CTB and CTA2/B are highly immunogenic
and can enhance specific immune responses when conjugated or co-expressed with
antigens. However, further investigations to explore the mechanisms of action of these
adjuvants including the potential to induce tolerance/autoimmunity, will allow more
effective use of these molecules in future vaccines.
Summary and Objectives
Many studies and a few failures in human and veterinary vaccines have led to a
growing belief that an efficacious vaccine for S. aureus infection will be difficult or
impossible to achieve. Unraveling the pathogenic and evasion mechanisms of S. aureus
will be important for the use of critical factors involved in these processes in vaccines.
Although there is evidence with other pathogens that a single antigen vaccine can be
effective, a multi-antigen vaccine approach will be essential for S. aureus. This is due to
the complex pathogenicity and expression of many different virulence factors. An
efficacious vaccine for S. aureus mastitis should include multiple highly conserved
antigens to protect against various strains, and a safe and immunogenic adjuvant.
Importantly, the vaccine must induce opsonizing antibodies, as well as cellular responses
and be able to target mucosal surfaces.
The overarching hypothesis of this research is that a mucosal, enterotoxin-based
vaccine containing multiple relevant antigens will protect cows against S. aureus
mastitis. To begin to address this hypothesis, the major aim of our research was to design
a mucosal cholera toxin (CTA2/B) adjuvant based mucosal vaccine for S. aureus caused
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mastitis. To achieve this aim, my dissertation work was focused on three distinct
objectives:
Objective 1: Expression, immunogenicity and variation of iron -regulated surface
protein A from bovine isolates of Staphylococcus aureus
IsdA is an important adhesin, virulence factor and invasin for S. aureus. It is
reported to be conserved in human isolates and a good vaccine candidate. The
determination of isdA genetic conservation and expression in bovine S. aureus is critical
for its use in a bovine vaccine. The outcomes of this objective were threefold. These
studies: 1) determined isdA conservation and IsdA expression from bovine S. aureus, 2)
identified and characterized variants of IsdA and the binding capacity of these variants to
FN and FG, and 3) identified the opsonizing ability of IsdA specific antibodies.
Opsonophagocytosis is a critical property of antibodies essential for S. aureus vaccine
efficacy.
Objective 2: Immunogenicity of mucosal Staphylococcus aureus vaccine for
bovine mastitis
There is currently no effective vaccine available to prevent bovine mastitis. To
develop a vaccine, the two conserved adhesins, IsdA and ClfA from S. aureus were used
in combination with CTA2/B adjuvant. The immunogenicity of this chimeric vaccine was
determined by two bovine trials completed during the dry off period. Milk and serum
from cows were used to detect humoral and cellular immune responses in addition to
detecting the opsonizing ability of vaccine-induced antigen specific antibody. The
outcomes of this objective included: 1) the mucosal vaccine (IsdA-CTA2/B and ClfACTA2/B) was able to stimulate humoral and cellular immune responses with largely a

32
Th2 bias, and 2) the antibodies stimulated against IsdA antigen were specific and capable
of opsonophagocytosis.
Objective 3: Immunoproteomics to identify Staphylococcus aureus antigens
expressed in bovine milk during mastitis.
S. aureus has many virulence factors required to adhere, invade, cause infection
and aid in survival and proliferation. A multivalent vaccine that can be target the diseases
associated with multiple strains and serotypes of the S. aureus will be more effective in
preventing S. aureus caused mastitis. In this objective, two-dimensional electrophoresis
(2DE) combined with mass-spectrometry was used for the detection of immunogenic
virulence factors and surface proteins from S. aureus. The outcomes of this objective
included: 1) the identification of 8 S. aureus surface proteins that are virulence factors
and were immunogenic in bovine milk in vitro, and 2) the evaluation of two proteins,
IsdC and EsxA as strong S. aureus vaccine candidates for incorporation into a bovine
mastitis vaccine.
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CHAPTER TWO: EXPRESSION, IMMUNOGENICITY AND VARIATION OF IRONREGULATED SURFACE PROTEIN A FROM BOVINE ISOLATES OF
STAPHYLOCOCCUS AUREUS
Abstract
Staphylococcus aureus iron-regulated surface protein A (IsdA) is a FG and FN
adhesin that also contributes to iron sequestration and resistance to innate immunity. IsdA
is conserved in human isolates and has been investigated as a human vaccine candidate.
The studies presented here describe the expression of isdA, the efficacy of anti-IsdA
responses and the existence of IsdA sequence variants from bovine Staphylococcus.
Clinical staphylococci were obtained from U.S. dairy farms and assayed by PCR for the
presence and expression of isdA. isdA-positive species from bovines included S. aureus,
S. haemolyticus and S. chromogenes. Immunoassays on bovine milk and serum
confirmed the induction and opsonophagocytic activity of anti-IsdA humoral responses.
The variable region of isdA was sequenced and protein alignments predicted the presence
of two main variants consistent with those from human S. aureus. Mouse antibodies
against one IsdA variant reduced staphylococcal binding to FN in vitro in an isotypedependent manner. Purified IsdA variants bound distinctly to FN and FG. These findings
demonstrate that variability within the C-terminus of this adhesin affects immune
reactivity and binding specificity, but are consistent with the significance of IsdA in
bovine disease and relevant for vaccine development.
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Introduction
Staphylococcus aureus (S. aureus) is one of the most prevalent pathogens causing
contagious subclinical and clinical bovine mastitis. Bovine mastitis is an inflammatory
disease of mammary tissues in cows, often represented by marked increase in somatic
cell count (SCC) [11,172–174]. Several pathogenic bacteria are known to cause bovine
mastitis; however, S. aureus causes persistent, difficult or impossible to treat infections
greatly impacting animal health [172–175]. This is the most economically important
disease for the dairy industry, largely due to loss of milk and the cost of treatment [176].
In the U.S. alone, the economic loss by bovine mastitis is estimated to be approximately
100-200$/cow [14,15,177,178]. The main treatment strategy adopted currently to treat
bovine mastitis is the use of antibiotics and management practices at dairy farms.
Excessive use of antibiotics is both a costly and risky option as it may lead to the
emergence of new antibiotic resistant strains. Efforts have been made for treating and
managing this disease, however, prevention by vaccination is the best approach. Effective
protection with a vaccine for a variable pathogen like S. aureus will require a vaccine
design which includes conserved virulence factors and determination of its antigenic
variation.
S. aureus possess a repertoire of virulence factors and surface adhesins, that
enables its survival in the varied physiological conditions of the host [63,179]. Iron
surface determinant (Isd) proteins are a class surface adhesins, that are involved in iron
acquisition and ECM binding [27,180]. Iron is a critical nutrient for survival of S. aureus
and its uptake is regulated by the FUR (ferric uptake regulator) regulator, in low iron
conditions [41]. The NEAT (near iron transporter) domain of Isd proteins is involved in
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haem binding from haemoglobin, for uptake into the bacterial cytosol [47,62]. As shown
in Figure 1-1 Chapter 1, the transfer of haem from membrane to cytoplasm is performed
by four or more Isd proteins (IsdA, IsdB, IsdC, IsdH) [44,181]. IsdA is one of the most
conserved of these proteins [45]. It is known to be critical for nasal colonization in
humans and provides hydrophobicity to the cells through a cell wall binding (LPTGX)
motif, aiding in colonization of S. aureus on the skin [29,182]. The NEAT domain in
IsdA is known to play a role in binding of IsdA to FN, however, the significance of the
C-terminal of IsdA in ECM binding is still not well described [25,77]. The C-terminus of
IsdA is involved in surface hydrophobicity, that confers resistance to the antimicrobial
peptides and fatty acid of the human skin [54]. These reports indicate that IsdA is an
important virulence factor for S. aureus that may contribute to infection in the bovine
udder.
The goals of this study were three-fold: 1) to determine the presence of isdA in
bovine isolates of Staphylococcus, 2) to determine the expression of IsdA in vivo as
determined by qPCR and anti-IsdA immune responses, and 3) to identify IsdA sequence
variation. Two main sequence variants were distinguished and the difference in binding
specificities and immune activity of the two distinct isdA allelic variants was defined.
The results of this study support the incorporation of the IsdA antigen in a multivalent
bovine vaccine, however, it is acknowledged that variability of this antigen will be an
important consideration for vaccine design.
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Materials and Methods
Bovine Milk, Serum and Staphylococcal Collection
Blood and quarter milk were taken from observationally healthy lactating
Holstein cows from Dairy 1 (D1; n = 53) and Dairy 2 (D2; n = 50) in the Northwest
USA. All bovine sample collection protocols were pre-approved by the University of
Idaho Institutional Animal Care and Use Committee (IACUC). SCCs were determined
using the Delaval method (Tumba, Sweden). Milk (100 μl) was plated on mannitol salt
agar (MSA) and MP2 Agar (Udder Health Systems Inc., Tacoma WA, USA) and cultured
at 37◦C for 24 h. Samples with yellow growth on MSA plus growth in the absence of
esculin hydrolysis on MP2 were presumptive staphylococci. Cultures were incubated in
lysis buffer (20 mM Tris Cl, 2 nM EDTA, 1.2% Triton X-100 + 20 mg/mL lysozyme, pH
8.0) for 30 min at 37◦C prior to DNA extraction (DNeasy, Qiagen, Valencia, CA, USA).
Milk was centrifuged to remove fat layers. Blood was allowed to coagulate at room
temperature. Milk and serum were diluted 1:10 in protease inhibitor (1:100 ThermoFisher HALT, 5% glycerol in 1× PBS) and frozen at −20◦ prior to ELISA. An additional
25 bovine Staphylococcus aureus isolates from clinically mastitic cows on 15 farms in
six US states were obtained (Udder Health Systems, Inc.) These strains had been
analyzed by mass spectrometry (MALDI). Species identification of all staphylococci was
confirmed by 16S rRNA sequencing (GE Healthcare, SeqWright, Houston, TX, USA).
Gene presence/absence was determined by electrophoresis of PCR performed under
optimized conditions, and amplicon sizes are as indicated (Table 2-1).
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Table 2-1. Bacterial strains, plasmids and primers used in this study
Bacterial strains
E. coli TE1
S. aureus Newbould 305
S. aureus MRSA USA300
S. aureus MRSA252 #75

Genotype or characteristics

Reference or source

∆endA derivative of TX1
Bovine clinical isolate
Human clinical isolate
Human clinical isolate

(8)
(9)
(10)
(11)

(8)

Plasmids
pBA015
pBA009A
pCK001

Gene

Vector

Reference or source

isdA (MRSA252)
isdA (MRSA252)
isdA (Newbould)

pET40(b)
pTRCHisA
pTRCHisA

(11)
(11)
This study

Primers

FW CGGTTCAACCAAAACCTGCT
RV GCGAAGGCAACTGTGCTAAT
FW CAAATGGCGAAGCACAAGCAG
RV CAAATGGCGAAGCACAAGCAG
FW AGCAGCACTGCAACAAATCC
RV CCATGGACCATTGGATCT
FW CCTATGCCAGTAGCCAATGTC
RV GCACCAAGCAGGTTATGTC
FW GTGAAAAACAATCTTAGGTAC
RVTATCAATAGCTGATGAATCCG
FW GCGATTGATGGTGATACGGTT
RV AGCCAAGCCTTGACGAACTAAAGC
FW GGGATCATAGCGTCATTATTC
RV AACGATTGTGACACGATAGCC
FW GGCCGTGTTGAACGTGGTCAAATCA
RV TACCATTTCAGTACCTTCTGGTAA
FW 8F AGAGTTTGATCCTGGCTCAG
RV 534R ATTACCGCGGCTGCTGGC

Gene

Amplicon
(bp)

Reference or Source

isdA

380

This study

isdB

138

This study

isdH

557

This study

clfA

318

This study

fnbpA

1750

(12)

nuc

270

(13)

mecA

527

(14)

tstaG

370

(15)

16s rRNA

530

(16)

RT-PCR, ELISA, Western Blot and Opsonophagocytosis
Total RNA was isolated from milk as described [183]. Briefly, milk was
centrifuged at 3000 × g for 15 min at 4◦C and pellets washed (1× PBS + 0.5 mM EDTA).
RNA was extracted (RNeasy, Qiagen), with an additional DNase (Promega, Madison,
WI) treatment (1U/100 μL, 30 min). cDNA was transcribed as described by the
manufacturer (High Capacity cDNA RT kit, Thermo Fisher) and included no RT
controls. 16S rRNA and isdA PCR were conducted on 2 μL of cDNA with primers (Table
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1) and GAPDH control. PCR (15 μL) was analyzed on 1% agarose with positive
(Newbould 305) and negative (no template). For milk and serum ELISA, a HIS-IsdA
fusion (pBA015, Table 2-1) was purified with cobalt chromatography as described [161].
Plates (Nunc, Thermo-Fisher) were coated with 50 μL of 10 μg/mL IsdA, and incubated
for 12 h at 4◦C followed by washes (1× PBS + 0.05% Tween 20). Blocking buffer (1×
PBS + 1% skim goat milk) was added for 2 h at 37◦C. Twofold dilutions, starting at 1:2
for milk and 1:10 for serum, were added and incubated at 4◦C for 12 h prior to washing
and addition of HRP-anti-bovine IgG (1: 10,000 Bethyl Laboratories, Montgomery, TX,
USA). Samples were developed with tetramethylbenzidine (TMB One, Thermo-Fisher).
Endpoint titers were defined as the reciprocal of the dilution giving an OD of 0.2.
Staphylococcus + and isdA ± cows used in ELISA are shown (Table S1, Supporting
Information). Ten cows from each farm, with both high and low SCC, and negative for
Staphylococcus by culture, were also assayed (Staphylococcus–isdA–). ELISAs are by
quarter for milk and by cow for blood. For westerns, IsdA (pBA015, 62 kD) was
separated on 12% SDS-PAGE, transferred to nitrocellulose strips and incubated in
blocking buffer (0.05% Tween-20 + 5% skim milk + 1× PBS) before probing with milk
at 1:500. HRP-antiboxing IgG (1:5000 Bethyl Labs, Montgomery, TX) was added and
strips were developed with Immobilon Western HRP substrate (Millipore, Billerica, MA,
USA). Opsonophagocytosis (OSP) was performed as described by [131] with the addition
of purified IsdA. IsdA (pCK001) was purified using cobalt as above for pBA015. Equal
volumes of 50 μg heat-inactivated serum were mixed with 50 μg purified IsdA and
incubated for 1 h at 37◦C. Equal volumes of S. aureus Newbould 305 (2 × 106) and
bovine PBMCs (2 × 106) were added to the reaction and incubated at 37◦C. At 60 min,
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cells were plated on MSA in triplicate. Results are reported as bacterial survival in
CFU/mL and compared to survival without PBMCs.
Table S1. Staphylococcus species from Dairies 1
and 2
CowID
QTR MP2a
D1-02
FL
γ
D1-07
BR
γ
D1-07
FL
γ
D1-07
FR
γ
D1-13
BL
γ
D1-13
FR
γ
D1-14
FL
α
D1-17
FR
β
D1-20
FL
β
D1-26
FR
γ
D1-43
BR
γ
D1-43
FR
β
D1-49
FL
β
D1-49
FR
α
D2-25
FL
β
D2-25
BL
β/α
D2-34
BL
β
D2-34
BR
β
D2-37
FL
β
D2-37
FR
β/α
D2-37
BL
β
D2-37
BR
β
D2-38
FL
β
D2-38
BR
β
D2-41
FL
β
D2-41
BR
β/γ
D2-43
FL
β
D2-43
FR
α
D2-43
BL
β
D2-43
BR
β
D2-44
FL
β
D2-44
FR
β
D2-44
BL
β/γ
D2-47
BL
β
a Hemolysis on MP2
b coagulase tube
c isdA PCR
d 16S rRNA sequence

CTb
+
+
+
+
-

isdAc
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-

Sequence IDd
S.agnetis
S.xylosus
S.chromogenes
S.haemolyticus
S.spp
S.spp
S.chromogenes
S.haemolyticus
S. aureus
S.chromogenes
S.agnetis
S.haemolyticus
S.saprophyticus
S.xylosus
S.chromogenes
S.chromogenes
S.devrise
S.haemolyticus
S. aureus
S.haemolyticus
S.haemolyticus
S.haemolyticus
S.haemolyticus
S. aureus
S.haemolyticus
S.haemolyticus
S. aureus
S.haemolyticus
S.haemolyticus
S.haemolyticus
S.haemolyticus
S.haemolyticus
S.haemolyticus
S.haemolyticus

Sequence Alignments and Predicted Tertiary Structure
The variable region of IsdA was predicted to comprise amino acids 222–308
(NCBI). Primers that encompass this region were used for isdA PCR and sequencing (GE
Healthcare). Alignments and evolutionary analysis were completed in MEGA 7 [184]. A
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rooted dendrogram of exhaustive pairwise IsdA alignments of 53 sequences (Table S2,
Supporting Information) was constructed using maximum likelihood based on the JTT
matrix-based model [184]. The I-TASSER server was used to visualize predicted IsdA
tertiary structures [50]. Model templates included the S. aureus hemoglobin-IsdH
complex and the NEAT domain of IsdA from S. aureus [185–188]. The Newbould 305
model has a C score of –1.93 (estimated TM score of 0.48 ± 0.15), and the MRSA252
model has a C score of –2.46 (estimated TM score of 0.43 ± 0.14). In the I-TASSER
server, the range of C scores is –5 to 2, with >–1.5 indicating correct global topology.
Table S2. IsdA sequences for phylogenetic analysis
Strain

Host

Variant

Accession

Newbould 305
RF122
LGA251
112808A
CVMN26035PS
S54F9
K12PJN53
SA7112
S123
ST772-MRSA-V
TCH130
TW20
JKD6008
ST228
Newman
CN1
Z172
04-02981
A8796
CGS01
CIGC348
FCFHV36
Gv69
NRS100
MRGR3
MRSA S4
MRSN 2761
TCH959
USFL270
DAR4145
MSSAT145
08-02300
6850
JKD6159

cow
cow
cow
cow
chicken
pig
pig
pig
pig
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human

I
I
II
III
I
III
II
III
III
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I

EJE55319
Q2YX95
CCC87810
EOR47976
KST23617
KPA00104
KII21536
KST55542
EPZ10793
ABX29083
253728336
CBI49003
ADL65130
CCJ22550
BAF67313
AGU61191
AGY89229
ADC37297
EFH35863
315196851
EHT89412
AKA99128
AIU85137
AHW66048
EOR40242
KSA20724
KKJ47858
KLM30023
CFE56532
AJE64530
SCS53121
ANI74018
AGU54846
ADL22931
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MO13
SA268
ST1413
MRSA252
CIGC341D
CIG149
08BA02176
TCH60
DR10
71193
S100
VET0293R
ST20130939
CA-347
SK1585
UK2
S. aureus subsp. anaerobius
S.schwertzeri
S. argenteus

human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human

II
II
II
III
III
III
III
III
III
III
III
III
I
III
-

AEV78123
AII55584
EWC67239
CAG40105
EHT84578
EHT78741
AFR73148
ADQ77565
EIA14898
AFH69349
EPZ05864
EZS55766
AMV90129
AGO29398
KFD32297
WP054190280
KKI67573
CDR24069
WP000160870

Anti-IsdA Mouse Serum
Mouse immunization protocols were pre-approved by the Boise State University
IACUC. Immunizations were performed as described [161]). Briefly, two groups of six
female BALB/c mice, 7 to 9 weeks old (Taconic, Hudson, NY), were administered 17 μg
purified IsdA (MRSA252 variant III, pBA009) + 5 μg native cholera toxin (CT, Sigma
Aldrich, St. Louis, MO, USA), or mock (PBS) in 10 μL 1XPBS applied to each nare by
pipette under light anesthesia on days 0 and 10. Blood samples were obtained by lateral
tail vein on day 14. Blood was allowed to coagulate and serum diluted 10-fold in protease
inhibitor (as above). IsdA-specific antibodies in serum were analyzed by ELISA as
described and endpoint titers defined as the reciprocal of the dilution giving an O.D. of
0.2 [65].
Adhesion Blocking and Ecm Binding Assays
For blocking assays, black walled (Nunc, Thermo-Fisher) 96-well plates were
coated with 50 μL of 10 μg/mL bovine FN (R&D Systems, Minneapolis, MN, USA) for
12 h at 4◦C. A 1:100 dilution of heat inactivated pooled mouse serum was mixed with 1 ×
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108 CFU of S. aureus MRSA252 or Newbould 305, grown in low iron media (LIM: 2 g
NaCl, 1.2 g NaHCO3, 1.6 g yeast extract, 6 g protease peptone/400 mL), for 30 min at
37◦C. A portion of 100 μL of the mixture was added to plates coated with FN and
incubated at 37◦C for 12 h prior to washing and addition of 150 μL Alamar Blue (0.1%
reazzurin in 1× PBS). Plates were read at 530/590 nm after 24 h. For binding assays,
IsdA from pBA009A and pCK001 was purified as above and separated on 12% SDSPAGE. Purified IsdA (100 μg) was added in 2-fold dilutions to 96-well plates coated with
10 μg/mL bovine FN or bovine FG (Alfa Aerar, Reston, VA, USA) and incubated at
37◦C for 12 h prior to washing and addition of mouse anti-HIS (1:1000 Sigma) and antimouse HRP secondary (1:10 000 Promega). Plates were developed (TMB One) and read
at 370 nm.
Graphing and Statistical Analysis
Graphing and statistical analysis was performed with JMP SAS software (Cary,
NC, USA). PCR and RT-PCR are representative of three independent assays; ELISAs are
reported as the means of three independent assays; and the OSP, adhesion and FN/FG
binding assays are triplicate means of one assay that is representative of three
independent assays. Significance for ELISA was determined using the non-parametric
Wilcoxon rank score (Mann-Whitney) test. Significance of OSP and adhesion assays was
determined using Student’s t-test. P-values are reported as P ≤ 0.05(∗), P ≤ 0.01(∗∗) or P
≤ 0.0001(∗∗∗∗).
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Results
Presence and Expression Of isdA In Bovine Isolates of Staphylococci
Blood and milk were obtained from 103 cows at two US dairies that differed in
size and operation. Presumptive staphylococci from milk were assayed by PCR for the
presence of isdA and 16S rRNA species identification. Four isolates of 34 (12%) were
Staphylococcus aureus and 19 were isdA positive (56%). Twenty-five additional clinical
bovine S. aureus isolates were obtained. The presence of isdA, and six additional
virulence factors, was assessed by PCR in all staphylococci (Table 2-2). isdA was
conserved in S. aureus (total of 28/29, 96.6%), and also present in S. haemolyticus
(11/17, 64.7%), S. chromogenes (2/5, 40%) and S. devreise (1/1, 100%). isdB was
conserved in all S. aureus (29/29, 100%), and other species harboring isdA. The adhesin
clumping factor A (clfA) was also highly conserved (28/29, 96.6%). To determine the
expression of isdA during mammary infection, we identified the presence of isdA mRNA
from total milk RNA. As shown in Fig. 2-1A, the majority of isdA positive
staphylococci-infected milk samples (Staphylococcus+ isdA+) contained isdA mRNA.
The staphylococcal culture from 14FL (D1) was negative for isdA by PCR, and the milk
sample was negative by RT-PCR. Two Staphylococcus +isdA+ samples had low CFUs,
and were inconclusive by RT-PCR (D1-26FR and D2-43FL). The expression of IsdA in
vivo was assessed by anti- IsdA ELISA of milk and serum. As shown in Figure 2-1B and
C, Staphylococcus+ isdA+ milk and serum samples had heightened anti-IsdA IgG
responses over samples negative for Staphylococcus (Staphylococcus– isdA–). A western
blot of purified IsdA probed with Staphylococcus+ isdA+ milk (cows D2 43FR and D2
37FR) compared to Staphylococcus – isdA – milk (cows D2 1FL and D2 6FL) supported
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the immunogenicity of IsdA in vivo (Figure 2-1D). To assess the efficacy of anti-IsdA
serum antibodies, we determined OSP of S. aureus Newbould 305 (Figure 2-1E).
Bacterial cells were mixed with bovine PBMCs and Staphylococcus–isdA– serum (low
anti- IsdA titer, light gray bars) or Staphylococcus +isdA+ serum (high anti-IsdA titer,
dark gray bars). Serum was preincubated in the presence or absence of purified IsdA to
block antibody activity. High anti-IsdA serum stimulated more bacterial killing than low
anti-IsdA serum (P ≤ 0.05), and purified IsdA significantly blocked bacterial killing in
the presence of high anti-IsdA serum (P ≤ 000.1).
Table 2-2 PCR analysis of adhesins from bovine staphylococcal isolates
Sequence ID

S. aureus
S. haemolyticus
S. chromogenes
S. agnetis
S. xylosus
S. devriesei
S. saprophyticus
S. spp.
Newbould 305
USA300

# of

# positive isolates (percent positive)

tot
al
isolates
29
17
5
2
2
1
1
3

isdA

isdB

isdH

clfA

fnbpA

nuc

mecA

28(96.6)
11(64.7)
2(40)
0
0
1(100)
0
1 (33.3)
+
+

29(100)
11(64.7)
2(40)
0
0
1(100)
0
1(33.3)
+
+

25(86.2)
0
0
0
0
0
0
0
+
+

28(96.6)
0
2(40)
0
0
1(100)
0
0
+
+

25(86.2)
4(23.5)
2(40)
0
0
0
0
0
+
+

26(89.7)
0
0
0
0
0
0
0
+
+

0
0
3(60)
0
0
0
1(100)
1 (33.3)
+
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Figure 2-1. In vivo expression and immunogenicity of Staphylococcus IsdA from
bovine milk and serum. (A) Expression of isdA from total RNA in bovine milk: RTPCR of (a) isdA (385 bps) and (b) 16S rRNA (530 bps). (B) IsdA-specific IgG
responses in milk and (C) serum as determined by ELISA on samples obtained from
Dairies 1 and 2. Samples are grouped as those from cows that were negative or
positive by culture of Staphylococcus in milk and those that are negative or positive
for isdA by PCR. Significance using the non-parametric Wilcoxon rank score test
(Mann-Whitney), P ≤ 0.05(∗) or P ≤ 0.01(∗∗), between cow groups is shown. (D)
Western blot (top) and corresponding SDS-PAGE (bottom) of anti-IsdA responses in
milk. Purified IsdA (62 kD) was probed with Staphylococcus–isdA– (D2-1FL, D2-6Fl)
and Staphylococcus +isdA+ (D2-43FR, D2-37FR) milk samples. (E) OPA of S. aureus
Newbould 305 with PBMCs and serum from Staphylococcus –isdA– (light gray bars)
and Staphylococccus +isdA+ (dark gray bars) cows. Significance using the pairwise
Student’s t-test, P ≤ 0.05(∗) between serum types or P ≤ 0.0001 (∗∗∗∗) between
treatment groups, is indicated. (Adapted from Misra et al. (2017) [184] )
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IsdA sequence analysis
Comparison of published S. aureus IsdA indicates that 86 amino acids within the
C-terminus are variable. This region is distinct from conserved iron-binding, hemebinding and NEAT domains of IsdA, as well as the C-terminal cell wall sortase signal
(Fig. 2-2A). The 380-bp variable region from all isdA +staphylococcal isolates were
amplified for sequencing and alignment. Figure 2-2 shows IsdA alignments from
staphylococci of the two dairies (B) and 23 S. aureus clinical isolates (C). One S. aureus
was negative for isdA by PCR and one was isdA+ but sequence could not be obtained.
Nucleotide differences within this region resulted in two main allelic variants that align
with bovine (Newbould 305, variant I) and human (MRSA252, variant III) IsdA.
Notably, variant III contains a characteristic four-amino-acid insertion near the Cterminus. Predicted tertiary structure models were constructed using IsdA from
Newbould 305 and MRSA252 (Fig. 2-2D) [50]. Models predict that the variable region
of IsdA has a coiled secondary structure with a solvent accessibility of 3–7 (0 = buried
residue, 9 = highly exposed). To determine if observed variation is consistent with human
S. aureus IsdA, phylogenetic analysis was completed with 53 published sequences
(Figure 2-3). Results included four cows, four pigs and one chicken isolate. Sequences
were largely conserved; however, differences within the variable region resulted in
clustering within two groups represented by MRSA252 (III, blue) and Newbould 305 (I,
red). A smaller subgroup consisted of those that contained only the characteristic fouramino-acid C-terminal insertion (variant II, green). Two strains (CA-347 and SK1585)
are closely related to variant II, but do not contain this C-terminal insertion.
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Figure 2-2. IsdA alignment and structure from bovine isolates. (A) Schematic
representation of IsdA structure including the conserved NEAT domain (red),
variable C-terminal regions (blue) and cell-wall-associated sortase signal (LPxTG,
green). Predicted amino acid alignment of the IsdA variable region from (B) 19 isdA+
Staphylococcus from Dairies 1 and 2, and (C) 23 isdA + S. aureus from mastitic bovine
milk across the USA, showing percent positive identity to S. aureus Newbould 305 and
MRSA252. (D) I-TASSER predicted tertiary structures of IsdA from Newbould 305
(variant I) and MRSA252 (variant III) S. aureus. Colors are representative of the
same regions as those in A. (Adapted from Misra et al. (2017) [184], thanks to Tyler
Wines for sequencing and alignment)
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Figure 2-3. Dendrogram of pairwise IsdA alignments of 53 published sequences.
Evolutionary analysis was performed with the maximum likelihood method based on
the JTT matrix-based model (MEGA, Version 7). Variants align into three main
groups, based on sequence differences within the variable C-terminus, representative
of Newbould 305 (I, red), MRSA252 (III, blue) and LGA251 (II, green). Isolates from
cow (∗), pig (∗∗) and chicken (∗∗∗) are noted. (Adapted from Misra et al. (2017) [184])
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Characterization of IsdA Variants
To assess if genetic variation of isdA could contribute to differences in protein
immune reactivity, we produced antibodies to variant III (MRSA252) in mice (Figure 24A) and used pooled serum to block S. aureus adhesion to FN. Antibodies produced against
variant III reduced FN binding of S. aureus MRSA252, but did not reduce binding of
Newbould 305 (Fig. 2-4B). Variants I and III were purified from Escherichia coli and
found to run at distinct sizes on SDS-PAGE (Figure 2-4C). ECM binding assays revealed
that variant I (Newbould 305) and variant III (MRSA252) had consistently distinct
interactions with FN, while variants bound similarly to FG (Figure 2-4D and E).
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Figure 2-4. Characterization of IsdA variants. Immune reactivity of variants
assessed by blocking S. aureus adhesion to FN in vitro with mouse antiserum. (A) IgG
anti-IsdA titers from mice vaccinated with IsdA (variant III, MRSA252) or
unvaccinated, and (B) adhesion of S. aureus Newbould 305 or S. aureus MRSA252 to
FN after incubation with pooled mouse serum from mice vaccinated with IsdA
MRSA252 (dark gray bars) or unvaccinated serum (light gray bars). Significance
using Student’s t-test, P ≤ 0.01(∗∗), between serum types is indicated. Binding
specificity of IsdA variants assessed by ECM binding assay: (C) SDS-PAGE of
purified IsdA from Newbould 305 (lane 1) and MRSA252 (lane 2), and binding of
purified IsdA from MRSA252 and Newbould 305 to (D) FN and (E) FG. (Adapted
from Misra et al. (2017) [184], thanks to Liwen Yang and Colton Knopp for mouse
study and FN binding assays)
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Discussion
S. aureus is a prevalent pathogen in humans and livestock [8]. This bacterium has
been investigated for decades, but its mechanisms of virulence are still not fully
understood. This study was aimed at evaluating IsdA as a potential bovine vaccine
candidate. The expression and variation of IsdA from a number of bovine S. aureus was
analyzed to advance the current understanding of its involvement in bovine disease. The
results from this study generated a number of outcomes and observations, including: 1)
the presence of isdA is strongly conserved in bovine S. aureus and it is also present in
some species of coagulase negative (CNS) Staphylococcus, 2) isdA is expressed in milk
from infected cows and induces antigen-specific responses, 3) anti-isdA antibodies are
active to induce opsonophagocytosis, 4) due to amino acid variation within the Cterminus, there are two-three main allelic variants of IsdA and 5) allelic variants bind
differentially to ECM proteins, indicating that the C-terminus is important for FN
binding. Use of targeted and conserved antigenic proteins is an essential characteristic
for a vaccine, especially for a highly variable pathogen like S. aureus, and this study
advanced our understanding of one important antigen.
While the presence of isdA in CNS strains of Staphylococcus indicates that this
antigen is not species-specific CNS staphylococci are also known to cause mastitis, and
infections are clinically relevant and may become chromic [189]. Other antigenic surface
proteins like ClfA and IsdB were also determined in this study to be conserved at the
genetic level, however, further characterization is required to investigate their
antigenicity. IsdB and ClfA both are reported potential vaccine antigens for human
vaccines [47,190]. Previous reports show a non-significant stimulation of immune
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responses by IsdB in human vaccines, however ClfA could be further characterized as an
antigen for bovine vaccine [77]. In this study, significant stimulation of anti-IsdA
immune responses in milk and serum was detected from cows currently infected with
isdA+ staphylococci, reflecting effective immune reactivity and surface exposure of the
IsdA antigen. The gene expression of isdA in milk also indicated that it is surface
exposed at the time of infection, further supporting its use as a target antigen for bovine
disease. However, a major limitation is of this study is that milk and blood samples were
taken at one time point, and no information is available on how long cows were infected,
or if cows had been infected previously. Thus, the efficacy, and the relevancy, of antiIsdA antibodies was assessed by opsonophagocytosis assay (OPA). OPA using antibodies
from serum of infected or uninfected cows shows stimulation of active immune responses
against IsdA, which were able to uptake and trigger phagocytosis of S. aureus. These
results indicate that IsdA is present and expressed from bovine Staphylococcus in vivo
and that this antigen induces active immune responses in vivo.
The NEAT domain of IsdA has a role in binding specificities and immune
reactivity, whereas the C-terminus is responsible for conferring hydrophobicity [54]. The
hydrophobicity provided by the C-terminus is very important for skin colonization of S.
aureus [54]. The results from multiple alignments in this study determined that there is
variation at the C-terminus of IsdA that results in the occurrence of two main allelic
variants. This variation is a result of amino acid insertions and a proline to histidine
substitution within the C-terminus. These allelic variants were represented by two
different strains of S. aureus; bovine (I, Newbould 305) and human (III, MRSA 252),
with variant I actually predominating in S. aureus isolated from both hosts. The NEAT
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domain of IsdA is known to bind to FG, and it is mostly conserved [62]. FN binding
experiments in this study, revealed that variation at the C-terminal influenced the binding
specificities of allelic variants, which suggests that the role of the C-terminus of IsdA is
to aid in the binding of FN. The limited sample size of this report however does not
support the conclusion that allelic variants have preference for either bovine or human
hosts. Current evidence suggests that that both allelic variants of IsdA may be important
for ECM interactions in bovine disease. Overall, the work presented here supports the
inclusion of IsdA in a vaccine designed to combat S. aureus caused bovine mastitis,
however, the incorporation of multiple alleles may be necessary.
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CHAPTER THREE: IMMUNOGENICITY OF A MUCOSAL STAPHYLOCOCCUS
AUREUS VACCINE FOR BOVINE MASTITIS
Abstract
Staphylococcus aureus causes a chronic, contagious disease of the udder, or
mastitis, in dairy cows. This infection is often refractory to antibiotic treatment, and has a
significant economic impact on milk production worldwide. An effective vaccine to
prevent S. aureus mastitis would improve animal health, reduce antibiotic dependence
and inform human vaccine approaches. The iron-regulated surface determinant A (IsdA)
and clumping factor A (ClfA) are conserved S. aureus extracellular-matrix adhesins and
target vaccine antigens. Here we report the results of two bovine immunogenicity trials
using purified IsdA and ClfA-cholera toxin A2/B chimeras (IsdA-CTA2/B and ClfACTA2/B). Cows were intranasally inoculated with IsdA-CTA2/B + ClfA-CTA2/B at dry
off and followed for 70 days. Trial 1 utilized three groups with one or two booster doses
at a total concentration of 600 or 900 g. Trial 2 utilized two groups with one booster at a
total concentration of 1200 g. Humoral immune responses in serum, milk and nasal
wash were examined by ELISA. Responses in serum were significant between groups
and provide evidence of antigen-specific IgG induction after vaccination in both trials.
Cellular proliferation was detected by flow cytometry using antigen-stimulated PBMCs
from day 60 of Trial 2 and revealed an increase in CD4+ T cells from vaccinated cows.
IsdA and ClfA stimulation induced Il-4 expression, but not IFN- or IL-17, in PBMCs
from day 60 as determined by cytokine expression analysis. Opsonophagocytosis of S.
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aureus confirmed the functional in vitro activity of anti-IsdA antibodies from Trial 2
serum and milk. The vaccine was well tolerated and safe, and results support the potential
of mucosally-delivered CTA2/B chimeras to protect cows from mastitis caused by S.
aureus.
Introduction
Bovine mastitis is one of the most prevalent and economically impactful diseases
of the dairy industry. The economic losses caused by this disease are estimated to be
$1.7-2 billion annually in the U.S. [14,15]. Multiple pathogens are capable of causing
bovine mastitis, leading to loss of milk yield and deteriorating animal health, however, S.
aureus causes contagious and difficult or impossible to treat subclinical and clinical
bovine mastitis [191,192]. S. aureus caused bovine mastitis is also of great concern due
to increasing antibiotic resistance and overall decrease in cure rates, especially for βlactamase positive isolates [193]. It has been reported that approximately 4-10% of cows
in U.S. are infected by S. aureus [174,194–196]. Management control practices on farms
have been successful in decreasing the rate of infection, however, S. aureus is known to
colonize skin and internalize inside mammary epithelial cells, alveolar cells, and
macrophages, which can limit antibiotic efficacy and lead to chronic, difficult to treat
subclinical infection [99]. An effective bovine S. aureus vaccine to reduce or eliminate
disease and prevent transmission would have large impacts on both animal and human
health [197–200].
There have been a number of attempts to design an S. aureus vaccine for bovine
mastitis. Approaches like whole cell vaccines, live attenuated vaccines, DNA vaccines,
toxoids, capsular polysaccharides and purified proteins have been used [129,201–204].
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Despite substantial progress, an effective vaccine that can protect cows against the
multiple strains and serotypes of S. aureus that cause mastitis is still needed. It is well
recognized that the use of multiple highly conserved and significant virulence factors will
be necessary to induce inter-strain protection. Additionally, the route of vaccine
administration and use of adjuvant for a mucosal and intracellular pathogen like S. aureus
is critical. A vaccine delivered mucosally, that could induce mucosal humoral as well as
cellular responses would reduce the colonization and adherence of S. aureus and aid in
preventing chronic S. aureus mastitis.
In this study, two bovine immunogenicity trials were performed to assess the
activity of a subunit vaccine comprised of purified iron regulated surface determinant
protein A (IsdA) and clumping factor A (ClfA) proteins combined with cholera toxin
(CTA2/B) adjuvant (IsdA-ACT2/B +ClfA-CTA2/B). CTA2/B is a safe and immunogenic
mucosal adjuvant from Vibrio cholerae made by genetically removing the toxic CTA1
subunit [161,163,205]. CTA2/B is known to stimulate cellular and protective immune
responses when co-administered with antigens [162–168, 203, 204].
We hypothesized that a CTA2/B adjuvant based mucosal vaccine would induce
antigen-specific humoral and cellular immunity, and will aid in reducing colonization of S.
aureus in the cow udder. Our results support the conclusion that intranasal administration
of the IsdA-CTA2/B+ClfA-CTA2/B subunit vaccine during the dry period can stimulate
significant antigen-specific immune responses in milk and serum and that the antibodies
are active and capable of triggering opsonophagocytosis.
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Materials and Methods
Bacterial Strains, Growth Conditions and Plasmids
Staphylococcus aureus Newbould 305 was used for the cloning of isdA and clfA
and opsonophagocytosis assay (OPA)[206–208]. S. aureus was grown Luria Broth (LB)
with shaking at 37°C for genomic DNA isolation and in low iron media (LIM) without
shaking at 37°C for OPA [33]. E. coli TE1 was used for cloning and protein expression
of HIS-tagged antigens from pCK001 and pMaH001 for ELISA (Table 3-1). These
strains were grown in LB for cloning, or terrific broth (TB) for protein expression, + 100
g/mL ampicillin at 37°C. E. coli Clear Coli BL21(DE3) (Lucigen, Madison, WI) was
used for expression of CTA2/B chimeras from pLR001 and pLR003 and grown at 37°C
in TB in presence of 35 ug/mL chloramphenicol. Plasmid pLR001 was constructed by
amplification of Newbould 305 genomic DNA using isdA-specific primers and ligation
into the vector pARLDR19 (SphI-ClaI) [169]. pLR003 was similarly constructed by
cloning into pARLDR19 (SphI-XhoI) using clfA-specific primers. pCK001 was
constructed by ligation of isdA from Newbould 305 into pTRCHIS (BamHI-HindIII) to
express HIS-IsdA. pMaH001 was constructed by cloning of Newbould 305 clfA, using
pLR003 as a template, into pBAD18 (NheI-HindIII) to enable expression of ClfA-HIS
into the E. coli periplasm. Strains, plasmid details and primer sequences (with restriction
sites underlined) are shown in Table 3-1. All plasmids were sequenced through cloning
junctions for confirmation.
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Table 3-1. Bacterial strains, plasmids and primers used in this study
Bacterial strains
E.coli TE1
E.coli ClearColi®
S. aureus Newbould 305
Plasmids

Genotype or characteristics
∆endA derivative of TX1
Lipid IVA modification of BL21(DE3)
Bovine clinical isolate

pLR001
pLR003
pCK001
pMAH001
Primers

Gene
isdA (Newbould )
clfA (Newbould)
isdA (Newbould)
clfA (Newbould)

Cloning
pLR001:

Vector
pARLDR19
pARLDR19
pTRCHisA
pBAD18

FW GCTACTGGCATGCGGCAACAGAAGCTACGAAC
RV GTGCATGATCGATTTTGGTAATTCTTTAGC
pLR003: FW GACTGGGCATGCAGGTGTAACTTCAACTGCTAAAG
RV GCATGGCTCGAGGGAATTGGTTCAATTTCACCAG
pCK001: FW GCTACTGGATCCGCGGCAACAGAAGCTACGAAC
RV GTGCATAAGCTTTCAAGTTTTTGGTAATTCTTTAGC
pMAH001: FW GATCCTCGCTAGCGGATGGAGTAAGACCATGG
RV GTACCAGAAGCTTTTAGTGATGGTGATGGT
GATGGGGAATTGGTTCAATTTCAC
Bovine cytokine qPCR:
FW GCATCGTGGAGGGACTTATGA
RV GGGCCATCCACAGTCTTCTG
FW CAGCATGGAGCTGCCT
RV ACAGAACAGGTCTTGCTTGC
FW CAGAAAGCGGAAGAGAAGTCAGA
RV TGCAGGCAGGAGGACCAT
FW GCCCACCTACTGAGGACAAG
RV GCTGGATGGTGACAGAGTTC

Reference or source
[79]
[79]
Lucigen, Madison, WI
[32]
Reference or source
This study
This study
This study
This study

Gene

Amplicon

Source

isdA

846 bp

[21]

clfA

840 bp

This study

isdA

852 bp

[21]

clfA

994 bp

This study

GAPDH

[80]

IL-4

[81]

INF-

[80]

IL-17A

[82]

Protein expression and purification.
Chimeras were purified as described [209]. Briefly, to express IsdA-CTA2/B and
ClfA-CTA2/B, ClearColi® (Lucingen, Madison, WI) transformed with pLR001 or
pLR003 was grown to an optical density (O.D.600) of 0.9 and induced for 24 h with 0.2
% L-arabinose. Proteins were isolated from the periplasmic extract with 1 mg/mL
polymyxin B and purified by affinity chromatography on immobilized D-galactose
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(Pierce™ D-Galactose Agarose, Thermo Fisher, Waltham, MA). Vaccine proteins were
dialyzed into sterile 20% glycerol + 1XPBS and protein concentrations determined by
BCA (Pierce™ BCA, Thermo Fisher). Vaccines were tested to ensure endotoxin levels
were below 0.05 EU/mL (LAL Endpoint Chromogenic, Lonza, Allendale, NJ) plated for
sterility and stored at -80C until use. For use in ELISA, IsdA and ClfA from Newbould
305 were isolated from the cytosol of E. coli Top10 (Thermo Fisher) containing pCK001
and pMAH001 after overnight induction with 1M IPTG. Proteins were then purified on
cobalt (HisPurTM, Thermo Fisher) under denaturing conditions and dialyzed into sterile
1XPBS. For use in flow cytometry and OPA, endotoxin was removed from these proteins
(PierceTM Endotoxin Removal Columns, Thermo Fisher).
Animals, Trial Design and Sample Collection
All animal protocols were pre-approved by the Boise State University
Institutional Animal Care and Use Committee. Approval was obtained from the State of
Idaho and USDA Center for Veterinary Biologics to transport exploratory vaccine.
Sample size was determined prior to Trial 1 by power analysis based upon predicted
immune responses in milk and serum. A sample size of 7 cows per group was predicted
to provide, at a 95% level of confidence, 92% power to detect a minimum difference
between the control and any other group of 15%. This was based on a univariate twogroup repeated measures analysis of variance (ANOVA), assuming that the between
groups error term is 0.13 and the within-groups error term is 0.08 [210]. Healthy Holstein
cows in the third or fourth lactation were enrolled in the study (21 total Trial 1, n =7; 22
total Trial 2, n=11). Animals were initially screened as those with at least one of two
previous somatic cell counts (SCC) counts below 200 x103 cells/mL and no clinical
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evidence of mastitis. Further enrollment criteria included: 1) no growth of S. aureus
culture from milk, 2) low baseline anti-IsdA responses in milk, and 3) no evidence of
bovine leukemia virus (BLV) infection. Cows were randomized into two or three groups
(Figure 3-2) and vaccinated on days 1, 14 and 49 (Trial 1) or 1 and 14 (Trial 2), and
followed until calving (Day Fresh = day 60 or 70). One cow in Trial 1 (Group 2) and four
cows in Trial 2 (Groups 1 and 2) left the study prior to day 60 due to unrelated
complications. Milk was not obtained from two additional cows in Trial 1 (Groups 1 and
3) because they did not freshen by day 70. The vaccine was delivered in 2.5 mL volumes
into each nare using a nasal cannula (Merck & Co., Kenilworth, NJ). Blood was isolated
from tail vein and allowed to coagulate at room temperature (RT) for 1hr prior to
centrifugation and resuspension into 1:10 Inhibitor Solution (IS =1X HALT TM protease
inhibitor, and 5% glycerol in 1X PBS), or collected as whole blood in vacutainer tubes
for peripheral blood mononuclear cell (PBMC) isolation (Becton Dickinson, Franklin
Lakes, NJ). Composite milk samples were taken aseptically after washing teat ends with
70% ethanol. Milk was centrifuged at 700 xg for 20 min at 4°C for removal of fat, and
skim milk was stored in 1:10 IS at -20°C prior to use in ELISA. Nasal antibodies were
obtained by insertion of absorbant cotton into each nare and resuspension of cotton into 5
mL of 1:10 prior to freezing at -20°C and use in ELISA. Nasal cultures were taken by
insertion of cotton swabs into each nare (Hygiena Q-swabTM, Thermo Fisher).
Milk Culture, PCR and Clinical Assessment
100 L and 10 L of milk and nasal culture were plated separately on MP2
(Udder Health Systems, Inc., Meridian, ID). The presence of small, white, esculinnegative colonies was considered presumptive staphylococcal species. These colonies
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were isolated and genomic DNA analyzed by PCR for confirmation of staphylococcal
species (primers, Chapter 2, Table 2-1), as well as the S. aureus-specific gene nuc, and
isdA and clfA. All animals were scored for the presence of clinical mastitis by
temperature and observation of udder on days of vaccination and milk sampling
[211,212]. SCC analysis was performed on milk using the California Mastitis Test (CMT,
Udder Health Systems, Inc., Meridian, ID).
IgG and IgA ELISA
IsdA and ClfA specific immune responses on serum, milk and nasal wash were
detected using ELISA, as described [161]. Briefly, 96-well microtiter plates (Nunc,
Thermo Fisher) were coated with 10 g of IsdA or ClfA in 50L 1XPBS, blocked for 2
hr at 37C in 1% goat milk + 1X PBS, and incubated with two-fold dilutions of bovine
serum, purified milk IgG or nasal wash from Trials 1 and 2. Dilutions were initiated at a
1:10 concentration of serum, and a 1:2 concentration of nasal wash for Trial 1, and for
Trial 2 the total IgG concentration was determined and concentrations of serum were
initiated at 50 g. Purified milk IgG was obtained using protein G affinity (NabTM Protein
G and ZebaTM Spin, Thermo Fischer) and dilutions for ELISA were initiated at 25 g
concentrations for both trials. Plates with antibody dilutions were incubated at 4°C for 12
hr prior to washing and addition of HRP-anti-bovine IgG (1:10,000 Bethyl Laboratories,
Montgomery, TX) or HRP-anti-bovine IgA (1:10,000 Bethyl Laboratories, Montgomery,
TX). Samples were developed with tetramethylbenzidine (PromegaTM TMB One, Thermo
Fisher) and read at 370 nm. Serum and milk ELISAs were performed on individual cows
for Trial 1 (n=6-7), or pools of 6-7 cows by vaccine group for nasal wash. For Trial 2,
ELISA results are reported using pools of 1-2 cows (n=5) for consistency with cellular
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analysis. Data are presented as the ratio of Day Fresh (or Day X for serum)/Day1 of the
optical density (O.D. 370 nm) from a representative antibody dilution in the linear part of
the curve. Results are the average of three independent assays.
PBMC Isolation, Flow Cytometry and Cytokine qPCR
PBMCs were isolated from whole bovine blood from Trial 2 on Day 60. PBMCs
were isolated using a density gradient established by layering whole blood diluted 1:2
with PBS on Histopaque®1077 (Sigma-Aldrich, St. Louis, MO). Blood samples were
centrifuged at 800 ×g for 30 min at room temperature. The buffy coat was removed and
washed 3 X with Hank’s buffered salt solution (HBSS) for 10 min at 400 ×g at room
temperature (RT) and counted with 0.2% Trypan blue. Mononuclear cells (PBMCs) were
then pooled such that each pool contained cells from 2 cows in each pool (n=4-5).
PBMCs (1 x 105) were plated in tissue-culture treated 96-well microtiter plates (Corning,
Sigma-Aldrich) and grown in RPMI-1640 at 37 °C, 5% CO2. Cells were stimulated with
10 µg of IsdA + ClfA endotoxin free antigen on days 1 and 3, and harvested on day 6.
Cells were then stained with 10 µL/106 cells anti-CD4 FITC (CC8, BioRad, Hercules,
CA) and anti-CD8 PE antibodies (CC63, BioRad), or equivalent amounts of isotype
control (IgG2a FITC, Becton Dickenson), for 30 min in the dark at 4 °C. Samples were
washed with 1xPBS, centrifuged at 400×g for 5 min, and resuspended in
3% FBS/0.02% NaN3/PBS. CountBrightTM absolute counting beads (10 µL) (Thermo
Scientific) were added to determine absolute cell numbers. Samples were analyzed for
fluorescence intensity on a FACS Calibur flow cytometer (Becton Dickinson) and
FlowJo data analysis software (Tree Star, Inc.). A minimum of 10,000 total lymphocyte
events were collected for each reaction. For cytokine assays, total RNA from day 6 of
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antigen stimulated pooled PBMCs (n=4-5) was extracted (RNeasy, Qiagen, Germantown,
MD) with an additional DNase I (Promega, Madison, WI) digestion. cDNA was reverse
transcribed as per manufacturer (High-Capacity RNA-to-cDNA™ Kit, Thermo Fisher).
qRT PCR was conducted using SYBR fast (Kapa Biosystems, Thermo Fisher) on
interferon gamma (IFN- ), interleukin-4 (IL-4) and interleukin-17 (IL-17) primers, using
bovine GAPDH as reference gene (Table 3-1). The data are presented as fold changes
determined by stimulated vs non-stimulated PBMC. All qRT-PCR experiments were
performed twice using biological triplicates.
Opsonophagocytic Assay (OPA)
OPA was performed as described [68,213]. Briefly, equal concentrations of
endotoxin free IsdA antigen (50 ug/well), and pooled (n=5) heat inactivated serum
(50ug/well) or purified milk IgG antibodies (50ug/well) from days 20 and 60/Fresh of
Trial 2 were mixed and incubated for at 37°C, 5% CO2 for 1 hour. After incubation, equal
volumes of S. aureus Newbould 305 (2x105 CFU) and bovine PBMCs (2x105 cells) were
added, and the reaction was further incubated for 90 minutes. PBMCs were isolated as
described above from whole citrated bovine blood (Hardy Diagnostics, Santa Maria, CA).
After 90 min, 10 l samples of reaction mixture were plated on MP2 in triplicate at
1:100,000 to determine CFU/mL. Results are reported as the percent killing, or the
reduction in CFUs/ml with serum/milk IgG compared to PBMC’s and S. aureus alone
without serum/ milk IgG.
Statistical Methods and Analysis
Serum ELISA results from both trials were analyzed using repeated measures
ANOVA on logged values in a mixed-model framework with compound symmetric
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within-cow covariance. Vaccine groups were explicitly compared on each day with
hypotheses not adjusted due to pre-planned comparisons. A Wilcoxon test in an exact
testing framework was used to compare vaccine treatments for Trial 2 flow cytometry
and qPCR data. Serum percent kill from OPA was analyzed as 3-way ANOVA (with and
without IsdA, vaccine group, and day) and within this model vaccine group was
compared within day and IsdA status, and IsdA status was compared within vaccine
status. Due to the nature and number of comparisons, sets of tests were adjusted for
multiple comparisons using the false discovery rate method [214]. Milk percent kill from
OPA was analyzed similarly to the serum, but in a 2-way ANOVA as only milk from day
of freshening was used. Logged humoral responses in the nasal wash were analyzed with
a 2-way ANOVA, with vaccine groups compared within each day (not adjusted due to
pre-planned comparisons). Logged values were used where necessary to stabilize
variance in residual plots, and nonparametric exact methods were used with the smallest
sample sizes and where logging did not correct the skew of the data. Statistical analyses
were conducted using JMP (Cary, NC) and SAS software (Cary, NC). P-values are
reported as p ≤ 0.05(*), p ≤ 0.01(**) or p ≤ 0.0001(****) and all reflect two-sided tests.
Results
Expression and Purification of IsdA-CTA2/B and ClfA-CTA2/B
CT is an enterotoxin from V. cholerae which acts as a stimulatory and delivery
mucosal adjuvant. The crystal structure of CT reveals an AB5 structure with a toxic A
subunit and non-toxic pentameric B subunit (Figure 3-1A) [133]. To construct a mucosal
subunit S. aureus vaccine, the toxic CTA1 domain (ctxA) was genetically replaced by
isdA or clfA, in the parental vector pARLDR19 (Table 3-1), to form a holotoxin-like
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CTA2/B chimera (pLR001 and pLR003, Figure 3-1B and D). IsdA-CTA2/B and ClfACTA2/B chimeras were expressed in E.coli using the leader sequence LTIIB of E.coli to
direct the secretion of IsdA-CTA2, ClfA-CTA2 and monomeric CTB to the periplasmic
space [29]. The folded subunits were purified from the periplasm using D-galactose
agarose affinity chromatography. The binding of CTB to the column and co-purification
with the CTA2 fusion indicates the formation of chimeric holotoxin. The expressed
chimeras were dialyzed, quantified and confirmed by SDS-PAGE (Figure 3-1C and 1E).
IsdA-CTA2 (38 kD) and ClfA-CTA2 (37 kD) were co-purified with CTB (11kD).
IsdA-HIS and ClfA-HIS were also purified from plasmids pCK001 and pMaH001 (Table
3-1). Expression was quantified and confirmed by SDS-PAGE for the use of these
proteins in ELISA.
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Figure 3-1. Construction and purification of S. aureus CTA2/B chimeric mucosal
vaccines. (A) ribbon diagram of Vibrio cholerae cholera toxin [38], (B) expression of
the IsdA-CTA2/B chimera from E. coli + pLR001, (C) SDS-PAGE of D-galactose
affinity-purified IsdA-CTA2/B (IsdA-CTA2 = 38kD, CTB = 11kD) vaccine
preparation, (D) expression of the ClfA-CTA2/B chimera from E. coli + pLR003, and
(E) SDS-PAGE of D-galactose affinity-purified ClfA-CTA2/B (ClfA-CTA2 = 37kD,
CTB =11kD) vaccine preparation.
Trial Design, Safety Assessment and Culture Analysis
Two immunogenicity field trials were conducted in healthy Holstein cows during
the dry-off period and shortly after parturition. Figure 3-2 shows the summary of trial
design. Trial 1 group 1 (red) received 300 g intranasal doses of IsdA-CTA2/B + ClfACTA2/B on days 1 and 14, group 2 (grey) was vaccinated on days 1, 14 and 49, and group
3 (light blue) received only mock (PBS) vaccination. Trial 2 group 1 (green) received 600
g intranasal doses of IsdA-CTA2/B + ClfA-CTA2/B on days 1 and 14 and group 2 (dark
blue) received PBS on these days. Animals were assessed during both trials for changes
in temperature, SCC and clinical outcome (Table 3-2), and milk/nasal wash samples were
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cultured for the presence of Staphylococcus and genotyping of isolates (Table 3-3). No
animals showed evidence of inflammation or clinical mastitis during either trial, and
temperatures, as well as SCC, were not affected by vaccination. No animals in either trial
were S. aureus positive in milk or nasal wash at any time. The presence of all
Staphylococcus, and those specifically harboring isdA and clfA, was monitored
throughout each trial by culture and PCR. These efforts revealed that vaccination had no
effect on the presence and numbers of Staphylococcus in general. In addition, while a
small number of animals were found to harbor isdA and clfA positive Staphylococcus
prior to vaccination (4 total, Trial 2, both groups, determined to be S. hemolyticus and S.
chromogenes), no isdA/clfA positive staphylococci was present after vaccination in any
group in either trial.
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Figure 3-2. Trial 1 and Trial 2 summary showing vaccination schedule, dosage,
sample collection and number of animals Groups are: 1) Trial 1, Group 1, vaccinated
2X on days 1 and 14 (red); 2) Trial 1, Group 2, vaccinated 3X on days 1, 14 and 49
(grey); 3) Trial 1, Group 3, not vaccinated (light blue); 4) Trial 2, Group 1, vaccinated
2X on days 1 and 14 (green); and 5) Trial 2, Group 2, not vaccinated (dark blue).

Table 3-2. Temperature and somatic cell count (SCC) from Trial 1 and Trial 2.
Trial
a

Temp

1
2
3
1
2
1
2
3
1
2

1

2
SCCb

Group

1

2
a

Day
Screenc

1

2

3

14

15

16

49

50

51

60

70

49.86
155.25
150.86
68.27
210.55

101.16
100.93
101.09
100.82
101.05
-

101.10
101.71
101.64
98.50
98.30
-

100.40
100.61
99.89
98.75
98.58
-

101.10
101.46
101.23
99.35
99.46
-

100.61
100.54
100.24
-

100.51
100.59
100.61
-

101.21
101.56
101.13
-

100.60
100.66
100.71
-

100.69
100.52
100.66
-

101.31
101.70
101.57
296
847.29
126.71
588.50
1079.8

101.34
101.77
101.06
851
52.33
132.14
71.50
68.50

temperature in Fahrenheit by rectal thermometer
SCC in cells/mL X1000 as determined by California Mastitis Test (CMT)
c sample taken on day of screening; -14 for Trial 1 and -9 for Trial 2.
b
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Table 3-3. Culture and genotyping of Staphylococcus
PCR
primers

Percent
Staph
positivea

Sequence
Staphylococcus: FW GGCCGTGTTGAACGTGGTCAAATCA
RV TIACCATTTCAGTACCTTCTGGTAA
S. aureus: FW GCGATTGATGGTGATACGGTT
RV AGCCAAGCCTTGACGAACTAAAGC
isdA: FW CGGTTCAACCAAAACCTGCT
RV GCGAAGGCAACTGTGCTAAT
clfA: FW CCTATGCCAGTAGCCAATGTC
RV GCACCAAGCAGGTTATGTC
Trial

Sample

Gene
tstaG

Amplicon
370 bp

Reference
[83]

nuc

270 bp

[84]

isdA

380 bp

[68]

clfA

318 bp

[68]

Group

Day
Screenb
1
14
49
60
70
nose
1
1
0
57
14
14
29
2
29
57
0
50
17
3
0
14
29
43
43
milk
1
14
0
2
29
17
3
29
14
milk
1
2
9
22
2
27
40
a percent of cows in each vaccine group positive for staphylococcal species as determined by culture and PCR.
b Groups are defined as: Trial 1: 1=vaccinated 2X, 2=vaccinated 3X, 3=mock; and Trial 2: 1= vaccinated 2X, 2=mock.

IsdA and ClfA-Specific Humoral Responses in Trials 1 and 2
Antigen-specific humoral responses were quantified by ELISA from blood, milk
and nasal wash collected during Trial 1, and from blood and milk collected during Trial
2. Results are reported as a ratio of Day X/Day 1 for serum and nasal wash, and Day
Fresh/Day 1 for milk. In Trial 1, group 2 (grey bars, Figure 3-3A), induced significantly
higher IsdA-specific IgG responses in serum on days 60 and 70 (p = 0.027 and 0.047,
respectively), with a consistent increase in vaccine group 1 (red bars), over unvaccinated
group 3 (light blue bars). Anti-IsdA IgG responses from group 2 on day 49 also indicated
an increase relative to unvaccinated group 3 (p = 0.080). Anti-ClfA responses were
supportive of an increase in ClfA specific IgG responses from groups 1 and 2 on days 60
and 70, but not significant (Figure 3-3B). Similarly, IsdA specific immune responses in
milk after freshening were the highest in vaccine group 2, followed by vaccine group 1,
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relative to unvaccinated group 3, but not significant (Figure 3-3C). Anti-ClfA responses
in milk were more variable, but with a lower ratio in the unvaccinated group compared to
both vaccinated groups (Figure 3-3D). In Trial 2, the vaccinated group 1 (green bars,
Figure 3-4A) showed a significant increase in the IsdA-specific IgG immune responses
over unvaccinated group 2 (dark blue bars) in serum on days 20 and 49 (p = 0.009 and
0.0003, respectively), and a supportive increase on day 60. Anti-ClfA responses in serum
were consistent with anti-IsdA responses, but were significant on day 20 only (p = 0.013)
(Figure 3-4B). IsdA-specific IgG responses in milk upon freshening were also higher for
the vaccinated group in this trial, but not significant (Figure 3- 4C). Lastly, the ClfA
antigen did not stimulate detectable IgG immune responses in milk over unvaccinated
(Figure 3-4D). Nasal wash anti-IsdA IgA was also assessed from pooled samples
obtained in Trial 1, and results are supportive of a stimulation of antigen-specific IgA,
especially within group 2 (Figure 3-5 grey bars, group 2 showing higher response than
group 3 on day 70 only, p = 0.043). Together, results demonstrate that antigen-specific
humoral responses can be stimulated after intranasal vaccination with IsdA-CTA2/B +
ClfA-CTA2/B.
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Figure 3-3. Trial 1 humoral responses in serum and milk. Anti- IsdA (A) and antiClfA (B) IgG responses as determined by ELISA using serum from days 14, 49, 60
and 70. Results are reported as ratios of Day X/Day (O.D.) at serum dilution of 1:320.
Anti-IsdA (C) and anti-ClfA (D) IgG responses as determined by ELISA using IgG
purified from milk on day 60 or 70 (Day Fresh). Results are reported as ratios of Day
Fresh/Day 1 (O.D.) at IgG dilution of 1:80 (3.125 g). Groups are: 1) vaccinated 2X
on days 1 and 14 (red), 2) vaccinated 3X on days 1, 14 and 49 (grey), and 3) not
vaccinated (light blue). Data are presented as the mean ± standard error for serum
(n=6-7), or quartile box plots with medians for milk (n=6). Significance (*) on Day 60
and Day 70 (p = 0.027 and p = 0.047) is shown.
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Figure 3-4. Trial 2 humoral responses in serum and milk. Anti- IsdA (A) and antiClfA (B) IgG responses as determined by ELISA using serum from days 7, 14, 20, 49,
60 and 70. Results are reported as ratios of Day X/Day 1 (O.D.) at serum dilutions of
1:1280 (400 ng total protein). Anti-IsdA (C) and anti-ClfA (D) IgG responses as
determined by ELISA using IgG purified from milk on day 60 or 70 (Day Fresh).
Results are reported as ratios Day Fresh/Day 1 (O.D.) at milk dilution of 1:80 (3.125
g). Groups are: 1) vaccinated 2X on days 1 and 14 (green), 2) not vaccinated (dark
blue). Data are presented as the mean ± standard error for serum or quartile box
plots with medians for milk (n=5). Significance (**) on Days 20 and 49 for anti-IsdA
responses (p = 0.009 and p = 0.0003) and (*) on Day 20 for anti-ClfA response (p =
0.013) is shown.
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Figure 3-5. Trial 1 humoral responses in nasal wash. Anti-IsdA IgA responses in
pooled nasal wash on days 14, 49, 60 and 70. Results are reported as ratios of Day
X/Day1 (O.D.) at a nasal wash dilution of 1:16. Groups are:1) vaccinated 2X on days
1 and 14 (red), 2) vaccinated 3X on days 1, 14 and 49 (grey) and 3) not vaccinated
(light blue). Data are presented mean ± standard error (n=3); significant difference
between vaccine groups 2 and 3 on day 70 (*, p = 0.043) is shown.
Induction of Cellular Immune Responses from Trial 2
The stimulation of T cell responses was assessed after the isolation of PBMCs
from cows on day 60 of Trial 2, and the stimulation of these cells in vitro with purified
IsdA+ ClfA antigen. Flow cytometry was used to determine concentrations of CD8+ and
CD4+ cells in stimulated and unstimulated groups (Figure 3-6A). Cows vaccinated with
IsdA-CTA2/B and ClfA-CTA2/B on day 60, show a significant increase in the
proliferation of CD4+ T cells after stimulation compared to the non-vaccinated control
group (p = 0.032; Figure 3-6B). The vaccinated group also revealed a modest increase in
the proliferation of CD8+ T cells. The levels of IFN-γ, IL-4 and IL-17 cytokine
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expression was also assessed by qRT-PCR from antigen (IsdA + ClfA) stimulated
PBMCs on day 60. PBMCs from cows immunized with IsdA-CTA2/B + ClfA-CTA2/B
revealed significantly higher expression levels of IL-4 upon stimulation (p = 0.016), but
no detectable increase in INF-γ or IL-17 (Figure 3-6C). These results indicate that the
mucosal immunization with IsdA-CTA2/B and ClfA-CTA2/B stimulated a Th2-type
cellular response.
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Figure 3-6. Trial 2 cellular and cytokine responses. Flow cytometric analysis to
determine proliferation of CD4+ and CD8+ T-lymphocytes from Day 60 after
stimulation with IsdA + ClfA: (A) representative light scatter dot plots showing the
gated bead and lymphocyte populations for unstimulated and stimulated PBMCs, as
well as the lymphocyte gated population of CD8-PE vs CD4-FITC, where the CD8
population falls in quadrant 3 (Q3) and CD4-FITC population in quadrant Q4, and
(B) quantification of flow cytometry showing the CD4+ T cell and CD8+ T cell
stimulation index in vaccinated (green) and unvaccinated (blue) groups. Significance
(*) for CD4+T cell stimulation is. (C) Quantitative RT-PCR to determine cytokine
expression from Day 60 antigen-stimulated PBMCs isolated from vaccinated (green)
and unvaccinated (dark blue) cows, showing: IL-4, INF- and IL-17 expression. Data
is reported as normalized Ct values fold change over GAPDH. Significance (*) for
CD4+ T cell (p = 0.032) and IL-4 expression (p = 0.016) is shown.
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Opsonophagocytic Activity of Isda Specific IgG Antibodies from Trial 2
The in vitro activity of antibodies stimulated against IsdA was assessed by OPA
using serum and milk from days 20, 60 and fresh of Trial 2 (Figure 3-7). Serum from
days 20 and 60 of vaccinated cows showed a significant increase in killing activity in the
absence of purified IsdA (p < 0.0001 and p = 0.009, respectively). When purified IsdA
was added to the assay, percent killing was reduced in the vaccinated group on both days
(p < 0.0001 and p = 0.001 for days 20 and 60, respectively) (Figure 3-7A and B). Purified
IgG from the milk of vaccinated cows upon freshening also showed significant
opsonophagocytosis activity in the vaccinated group relative to the unvaccinated group (p
= 0.041), and consistent blocking of killing activity in the presence of IsdA antigen in the
vaccinated group (p = 0.010) (Figure 3-6C). Overall results of this assay indicate that,
antibodies stimulated against IsdA are active against isogenic S. aureus in vitro and
induce significant opsonophagocytic responses.
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Figure 3-7. In vitro activity of anti-IsdA responses from Trial 2 serum and milk.
Opsonophagocytic assay (OSP) to determine the ability of anti-IsdA humoral
responses from days 20 (A) and 60 (B), or pooled milk from day Fresh (C), of
vaccinated (green) and unvaccinated (dark blue) cows, to promote phagocytic killing.
Samples were also pre-mixed with (+IsdA) or without (-IsdA) purified IsdA to assess
the inhibition of serum activity. Results are reported as percent killing (CFU/mL) of
S. aureus Newbould 305 by bovine PBMCs after mixture with pooled serum
compared to a control of PBMCs plus S. aureus in the absence of serum (n=5). Pvalues are adjusted for false discovery rate [214]. Significance between serum in
vaccine groups without IsdA on days 20 and 60 is shown (p = < 0.0001 *** and p =
0.009 ** respectively); as is significance between IsdA presence and absence on days
20 and 60 (***, p < 0.0001 both days); in milk, vaccine groups differ (p = 0.041) and
in the vaccinated group, percent killing differs by IsdA status (p = 0.01,* shown).
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Discussion
Bovine mastitis is one of the most important diseases of the dairy industry and
developing methods of prevention is a top priority. New approaches that can induce
complex responses to block colonization and transmission are needed. In this study, we
describe the results of two clinical trials using a mucosal subunit vaccine (IsdA-CTA2/B +
ClfA-CTA2/B) against S. aureus caused bovine mastitis. Both trials were conducted at the
start of the lactation dry period, vaccine was administered intranasally and boosted either
one or two times during the trial. Blood and milk samples were collected during and at the
end of the trial to detect immune responses. Significant antigen-specific immune responses
were detected in the serum of vaccinated animals in both the trials. In Trial 2, cytokine
expression profile revealed that vaccine induced immune responses were largely Th2-type.
Importantly, the antibodies that were stimulated were specific to IsdA, active and effective
in triggering opsonophagocytosis in vitro. The IsdA-CTA2/B + ClfA-CTA2/B vaccine was
found to be safe and well tolerated intranasally, at dosage as high as 1200 µg.
IsdA is a FN and FG binding surface adhesin from S. aureus, it also contributes to
iron sequestration, surface hydrophobicity and lactoferrin resistance. Multiple reports have
described IsdA as a central human antigenic vaccine target [62,64,161]. ClfA is an FN
adhesin, also known to be conserved and immunogenic [124,195,209]. As described in
Chapter 1, ECM binding is critical for colonization of S. aureus in the cow udder, as this
interaction potentiates its uptake intracellularly into various cells like, macrophages,
neutrophils, mammary gland epithelial cells (MacTs) [215,216].
Our results from both the trails indicated that there is an antigen-specific increase
in humoral immune responses in vaccinated animals. Both IsdA and ClfA stimulated
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immune responses, however, immune responses stimulated against IsdA were consistently
higher in both trials, as compared to ClfA. This may be due to the structure and differential
stability of IsdA-CTA2/B compared to ClfA-CTA2/B. The antigenic surfaces exposed
during folding of chimera could facilitate higher antibody stimulation with more specificity
for IsdA [217,218]. Also, antigens combined with CTA2/B chimeras can potentially lose
their tertiary structure, which is a limitation that can influence antibody stimulation and
specificity [219]. The results from OPA indicated that anti-IsdA antibodies were induced
and were responsible for the majority of the in vitro killing activity of S. aureus. These
results indicate that, while anti-IsdA responses were induced to a higher level, addition of
ClfA was beneficial, and this antigen may have contributed to cellular responses. Future
incorporation of additional antigens will be essential to optimize efficacy.
Successful prevention by vaccine relies on the timing of vaccination and booster
doses thereafter. In Trial 1, there were two vaccinated groups and one unvaccinated. The
group that was vaccinated twice (1) was compared to group 2 vaccinated three times and
the unvaccinated group. There was a slight but supportive booster effect seen after the third
dose of vaccination in group 2 In Trial 2, the vaccination was administered at a higher dose,
which induced higher immune responses in serum over the 50-day period of vaccination
with a more distinct booster effect, however these responses declined sharply during the
freshening period. Despite this drop, anti-IsdA IgG antibodies in milk were consistently
elevated in vaccinated animals upon freshening. Importantly, milk antibodies from this
trial, in which cows had received the last booster on day 14, were active and effective in
OPA despite having lower serum responses. Opsonophagocytosis, or the demonstration of
functional antibody activity, has been described as critical for a successful S. aureus
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vaccine [220]. Here we revealed that the opsonophagocytic antibodies stimulated from
both serum and milk during freshening were highly significant, antigen-specific, and
supportive of their protective capacity.
Another key feature required for the success of a subunit vaccine is an adjuvant.
Adjuvants are important for targeted delivery, antigen presentation and stability of the
vaccine. CT, is a gold standard mucosal vaccine adjuvant that has been used extensively in
animal studies [221–223]. CT has been reported to have anti-inflammatory properties
[224,225]. CTA2/B is a genetically engineered CT chimera that was first described as a
mechanism to make stable human vaccines with the antigen directly coupled to a functional
CTB subunit [226–229]. CTA2/B chimeras have advantages over CT for use as mucosal
vaccines, including: the absence of the toxic A1 domain, the non-covalent association of
antigen and adjuvant, and a native receptor-binding subunit that retains the A2 ER-targeting
KDEL motif [136]. Evidence suggests that an A2/B chimeric structure may promote
antigen uptake and presentation, resulting in efficacy in animal models [170,171,230]. Our
results support the use of CTA2/B chimeras for bovine vaccination, and suggest that
intranasal vaccination with CTA2/B can induce antigen-specific antibody production at the
mucosal surface and in milk.
Despite decades of research, S. aureus has proven to be a difficult pathogen to
eliminate. The development of an effective vaccine to prevent bovine mastitis caused by S.
aureus would reduce bovine morbidity and mortality, increase food production and quality,
reduce antibiotic use and potentially inform human vaccine development. This report
describes the novel approach that may address these needs. Results are supportive of the
continued assessment of CTA2/B chimeras as bovine vaccines to prevent S. aureus mastitis.
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CHAPTER FOUR: IMMUNOPROTEOMICS TO IDENTIFY STAPHYLOCOCCUS
AUREUS ANTIGENS EXPRESSED IN BOVINE MILK DURING MASTITIS

Abstract
Staphylococcus aureus is an opportunistic pathogen affecting both human and animal
species. An effective vaccine to prevent S. aureus bovine disease and transmission would
have positive impacts on animal well-being, food production and human health. The
objective of this study was to identify multiple immunogenic antigens that are involved in
udder colonization and disease for incorporation into a vaccine to prevent bovine
mastitis. S. aureus produces a number of cell wall anchored and surface-associated
virulence factors that play key roles in the pathogenesis of mastitis. Many of these
proteins are conserved between different strains and serotypes of S. aureus, and represent
promising vaccine candidates. In this study, we utilized an immunoproteomics approach
to identify antigenic proteins from the surface of S. aureus. The expression of cell wall
and surface proteins from S. aureus was induced under low iron conditions, followed by
trypsin extraction and separation by two-dimensional electrophoresis (2DE). The
separated proteins were blotted with antibodies from mastitic bovine milk, and identified
by liquid chromatography-mass spectrometry (LC/MS/MS) analysis. Thirty-eight unique
proteins were identified, of which eight were previously reported to be involved in S.
aureus virulence. Two immunogenic surface proteins; IsdC and EsxA, were cloned,
expressed, and purified from E.coli for confirmation of immune reactivity by ELISA.

82
Amino acid alignments of published S. aureus sequences indicated that IsdC and EsxA
are highly conserved. PCR on 37 bovine S. aureus isolates determined that the presence
of esxA and isdC is also conserved. The immunoproteomics technique used in this study
generated reproducible results and identified at least two promising vaccine antigens for
use in novel vaccines to prevent bovine mastitis.
Introduction
Bovine mastitis is an important and economically relevant disease that affects the
dairy industry worldwide [175,231]. This disease causes large economic losses every
year; estimated to be as high as $2 billion/year in the U.S. alone [15,232]. These losses
are mainly due to reduced milk yield, antibiotic therapy, veterinary services and the
reduced price of culled animals [178,233]. Mastitis is most often an acute or chronic
inflammation of mammary glands caused by bacterial infection, and commonly leads to
increased somatic cell count (SCC), cytokine production, antibody secretion and bacterial
load in milk [105,234]. Multiple pathogens are known to cause bovine mastitis, however,
S. aureus is one of the most commonly isolated pathogens in milk, and an estimated 3%
of dairy cows worldwide are infected [235]. S. aureus infection often results in chronic,
subclinical disease that is highly contagious, and difficult or impossible to treat, with cure
rates lower than 25% [236] . Despite decades of research, an effective vaccine that can
prevent S. aureus bovine disease is not yet available; largely due to strain to strain
variability and redundancy of S. aureus virulence factors. The strategy to design effective
vaccines for S. aureus mastitis must include multiple conserved and immunogenic
virulence factors that can provide cross-protection for the many strains of this bacterium.
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S. aureus expresses a broad range of virulence factors, that include surface
proteins covalently attached to the cell wall and secreted proteins expressed during
infection [237]. These exposed proteins are essential for the survival and proliferation of
S. aureus, and the presence of many of them is conserved [238,239]. Depending upon
the stage of infection and physiological conditions inside the host, virulence factor
expression will promote binding to the extracellular matrix (ECM), colonization,
invasion, and avoidance of the immune response [240]. A number of these factors have
been emphasized in both human and veterinary vaccines as important targets effective for
vaccine development [201]. The iron-regulated surface protein A (IsdA) is an S. aureus
surface adhesin that is also involved in iron sequestration and found to be highly
expressed, conserved and immunogenic during in bovine mastitis [184]. Other adhesins,
such as: IsdB, ClfA and HlA, also have antigenic properties in models for human S.
aureus infection, however, their role in bovine disease requires further exploration
[68,241].
Proteomics is an important tool to identify potential vaccine antigens, especially
for pathogens like S. aureus with numerous surface exposed proteins [242,243]. Studies
have reported the use of two-dimensional electrophoresis (2DE) for whole or subcellular
proteome analysis of S. aureus for human vaccine development [244]. Couto et al.
(2016), recently described the use of the SERPA (serome proteome analysis) technique to
explore and characterize novel vaccine and therapeutic targets for S. pseudointermedius
infections in dogs [245]. Mastitic cow milk specifically contains neutrophils,
lymphocytes and antibodies as a result of infection and subsequent inflammation [92].
Immune cells, secreted antibodies and cytokines present in milk during S. aureus acute or
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chronic infection are important tools to identify bacterial antigens relevant to disease.
Immunoproteomics utilizes a combination of proteomics and immunoblotting to identify
antigenic proteins and factors. SERPA combined with immunoproteomics has been
employed to identify antigenic proteins using serum from infected cows with subclinical
mastitis [246,247]. In addition, various bioinformatics tools, such as reverse vaccinology
and in-silico approaches, have also been explored to analyze the surface proteome of S.
aureus with a focus on vaccine antigenic targets [26,248,249]. Important contributions
have been made using these techniques, however more immunologically extensive and
disease-, as well as host-, specific approaches are needed for an effective S. aureus
vaccine against bovine mastitis.
In this study, our aim was to use mastitic milk antibodies to identify relevant
antigens for the prevention of bovine mastitis. Here we report that 2DE, coupled with
immunoblotting and mass spectrometry, promoted the identification of immunogenic
vaccine candidates from S. aureus. We characterized and prioritized these candidates in
silico, and cloned and purified the antigens, EsxA and IsdC. EsxA and IsdC were
confirmed by ELISA to be immunogenic and surface exposed during S. aureus infection
of the udder. In addition, sequence analysis and PCR on genomic S. aureus DNA
indicated that EsxA and IsdC were conserved and the presence of these antigens is found
on the majority of bovine isolates. This is the first known report of the use of
immunoproteomics to identify S. aureus antigens using milk from cows with mastitis.
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Materials and Methods
Bacterial Strains, Culture Conditions and Milk Samples
The S. aureus strains used in this study were Newbould 305 [208], a clinical strain
(C1, kindly donated by M. McGuire) and 37 additional clinical bovine S. aureus isolates
(kindly supplied by Udder Health Systems Inc, Meridian, ID). Bovine S. aureus was
characterized and confirmed by growth and haemolysis on MP2 agar (Udder Health
Systems, Inc.), coagulase production, and 16s rRNA sequencing. For genomic DNA
isolation, S. aureus was grown in Luria Broth (LB) with shaking at 37C. For cell wall
protein and surface adhesin expression, S. aureus was grown in low iron media (LIM)
[250] with shaking at 37°C. For use in 2DE, milk from four different clinically mastitic
cows was obtained from a diagnostic laboratory after confirmation of the presence of S.
aureus by mass spectrometry (MALDI, Udder Health Systems Inc., Meridian, ID). Milk
was pooled and 10 and 100l was plated on MP2 agar for CFU determination (1.7x107
CFU/ml), S. aureus isolation, and confirmation as described above. Commercially
available pasteurized milk, and pooled unpasteurized milk obtained from 5 S. aureus
negative cows, was used as negative milk for comparison in 2DE. Unpasteurized milk
obtained from five S. aureus infected cows and five S. aureus uninfected cows was used
for ELISA. Collection and processing of milk for ELISA and negative control milk is
described previously [184].
Isolation of S. aureus Cell Wall Associated Proteins
Cell wall associated proteins were isolated using trypsinization as reported [21].
Briefly, S. aureus Newbould 305, S. aureus C1, and E.coli (DH10- Top10, Thermo
Fisher) were grown in LIM overnight to an O.D. of 0.75-1.2 and harvested by
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centrifugation (6000 ×g for 10 min at 4°C), prior to washing three times with 1x PBS
(Table 1). Cells were then resuspended in 1/50 volume of the original culture in1x PBS
containing 40% sucrose (pH 7.4) for 5 mins. Digestion was carried out with the addition
of 50 μg of trypsin plus 2 mM DTT for 1hr at 37°C. The digested mixture was
centrifuged at 3500 ×g for 10 min, and the supernatant with peptides was filtered with a
0.22 μm filter. Protease reactions were stopped with protease inhibitor solution (Halt
Protease Inhibitor Cocktail 100X, Thermo Fisher Scientific, Waltham, MA). Total
protein was analyzed by SDS-PAGE and measured for concentration using BCA (Pierce
BCA protein assay kit, Thermo Fisher).
Table 4-1. Bacterial strains, plasmids and primers used in this study.
Bacterial strains
S. aureus Newbould 305
S. aureus Clinical
E.coli Top10

Genotype/relevant information
Bovine clinical isolate
Bovine clinical isolate
DH10

Reference or source
[208]
This study
Invitrogen (Thermo Fisher)

Plasmids
pNM002
pNM003

Gene
esxA (Newbould 305)
isdC (Newbould 305)

Vector
pTRCHisA
pTRCHisA

Reference or source
This study
This study

Primers
PCR
esxA: FWGGCAATGATTAAGATGAGTCC
RVGCAAACCGAAATTATTAG
isdC FWGAGTATCGAAGGACATAAAG
RVGCTAAGGATGCAACTGG
Clones
pNM002:
FWGCTTCCGGGATCCGCAATGATTAAGATGAGTCCAG
RVCAGTGCGGAATTCTTATTGCAAACCGAAATTATTAG
pNM003:
FWGCTTCCGGGATCCGCAGATAGCGGTACTTTGAATTATG
RVCAGTGCGAAGCTTTTATTCCACATTGCCTTTAG
pCK001:
FWGCTACTGGATCCGCGGCAACAGAAGCTACGAAC
RVGTGCATAAGCTTTCAAGTTTTTGGTAATTCTTTAGC

Amplicon (bp) Source
287
This study
384
Gene

This study
Amplicon
(bp)

Source

esxA

297

This study

isdC

606

This study

isdA

852

[65]
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Two-Dimensional Gel Electrophoresis (2DE) and Western Blotting
Trypsinized protein extracts were cleaned using the ReadyPrep 2-D Cleanup kit
(Bio-Rad, Hercules, CA) following manufacturer’s instructions, and resuspended in
ReadyPrep rehydration buffer. A total of 150 lof 165 g/ml of protein was used to
rehydrate a 7 cm immobilized pH gradient (IPG) strip (Bio-Rad, Hercules, CA), pH 4-7
for 24 hrs. Rehydrated IPG strips were then iso-electro focused (IEF) on the first
dimension using the Protean IEF system (Bio-Rad) at cycles 250 voltage for 20 min
linear followed by 4000 volts for 120 min and 4000 volts at 10,000V-hr rapid. After IEF
strips were equilibrated using equilibration solution I and II (2-D Starter kit, Bio-Rad) for
15 min each. For second dimension separation, the equilibrated strips were run on 12%
SDS-PAGE and stained with Coomassie blue. 2D gels were electro-transferred to a
polyvinylidene difluoride (PVD) membrane and blocked using blocking buffer (0.05%
Tween 20 + 5% skim milk + 1× PBS). Membranes were washed and blotted with pooled
mastitic milk or S. aureus negative milk (1:5000, dilution). The membrane was
developed using the ECL western blotting substrate (Pierce, Thermo Fisher) and exposed
to film for 24 hours to detect chemiluminescence.
Reported data represent 5 independent blots performed using pooled mastitic milk
on separated proteins from S. aureus Newbould 305. Additional blots for comparison
were performed each at least twice, using: 1) uninfected pasteurized milk on proteins
from Newbould 305, 2) pooled unpasteurized milk from 5 S. aureus negative cows on
proteins from Newbould 305, 3) pooled mastitic milk on trypsinized proteins from E.coli,
and 4) pooled mastitic milk on trypsinized proteins from S. aureus C1. Spots identified
on the western blot film were compared and aligned to the Coomassie blue stained 2D gel
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using ImageJ software (https://imagej.nih.gov/ij/ ) to enable the selection of proteins with
the brightest spot. Only those proteins showing prominent bright spots on S. aureus
Newbould 305 or C1 immunoblots using S. aureus infected milk were picked for
identification by mass spectrometry.
Mass Spectrometry Analysis
The proteins aligned with the brightest spots on the western were picked using a
spot picker and digested with trypsin as described with modifications [245]. Briefly, gel
spots were destained in buffer (50 mM ammonium bicarbonate/50% acetonitrile, reduced
in 10 mM DTT) for 60 min at 56oC, and alkylated in 55 mM iodoacetamide for 60 min at
room temperature (RT) in the dark. Proteins were then digested with 20 µg/ml trypsin
overnight at 30oC. Peptides were extracted from the gel, dried under vacuum, and
reconstituted in buffer (5% acetonitrile, 0.1% formic acid in water) for LC-ESI-MS/MS
analysis. 5 L of peptide mixture was injected onto a C18 reverse-phase column (10 cm x
75 µm, 3 µm, 120 Å). A linear gradient with two mobile phases at a flow rate of 300
nL/min was used to separate peptide mixtures. Full scan MS spectra were acquired from
m/z 300-2000.
Collision-induced dissociation (CID) was used to fragment the precursor ions.
MS/MS spectra were acquired in the data-dependent acquisition mode for the top ten
most abundant precursor ions in the preceding full MS scan. Peptide spectral matching
and protein identification were achieved by database search using Sequest HT and
Mascot algorithms in Proteome Discoverer 1.4 (Thermo Scientific, Waltham, MA, USA).
Raw spectrum data were searched against the UniProtKB/Swiss-Prot protein database for
S.aureus (www.uniprot.org/ , obtained on June 14, 2016). Immunogenic proteins were
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ranked on the basis of location and function using the PSORTb v3.0.2
(www.psort.org/psortb/) and UniProt (www.uniprot.org), and adhesion potential using
Vaxign (www.violinet.org/vaxign/) (Table 2 and Supplementary Table 1).
Pcr, Cloning and Purification of Recombinant Proteins
Gene presence/absence was determined by electrophoresis of PCR products
performed three times under optimized conditions. Primer an amplicon sizes are as
indicated (Table 1). The plasmids; pNM002 and pNM003 were constructed for the
expression of His-EsxA and His-IsdC. Corresponding primers for isdC and esxA (Table
1, restriction sites underlined) were used to PCR amplify genomic DNA from S. aureus
Newbould 305. The resulting product was cloned into pTrisHisA (Invitrogen, Carlsbad,
CA) and plasmids were transformed into E.coli Top10 (Thermo Fisher). Plasmids were
confirmed by sequencing through the junctions. Transformed cells were induced and
proteins were isolated from the bacterial cytosol for purification by cobalt affinity
chromatography (Talon Metal Affinity Resin; Clontech Laboratories, Mountain View,
CA) under denaturing conditions. Purified proteins were dialyzed against phosphatebuffered saline (1x PBS) with 5% glycerol, analyzed by SDS-PAGE, and confirmed by
mass spectrometry. Protein concentrations were determined by BCA as described above.
ELISA
ELISA was used to detect antigen-specific antibody responses in milk from five
S. aureus infected cows and compared to five uninfected controls. Microtiter plates
(Nunc, Rochester, NY) were coated with 10 g of purified protein (EsxA and IsdC,
described above) per well in 1x PBS, blocked with buffer (1% skim milk + 1x PBS), and
incubated with 2-fold dilutions of bovine milk, starting at 1:10 dilution, for 12 hr at 4°C.
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Plates were then washed with PBS-T (1× PBS + 0.05% Tween 20), incubated with HRPconjugated anti-bovine IgG (1:10,000; Thermo Scientific, Rockford, IL) in blocking
buffer for 1 hr at 37°C, washed again and developed with tetramethylbenzidine (TMB
One, Promega, Madison, WI). IgG titers were calculated after background values
(protocol minus samples) were subtracted. Endpoint titers were defined as the reciprocal
of the dilution giving an OD of 0.2, and results are representative of the assay performed
independently three times.
Data and Statistical Analysis
Graphing and statistical analysis was performed with JMP SAS software (Cary,
NC). Significance for ELISA was assessed using two-tailed Student’s t-test for unequal
variance. Values are reported as p ≤ 0.05(*). Decoy database search was performed to
calculate false discovery rate (FDR) of mass spectrometry data. Proteins containing one
or more peptides with FDR≤0.05 were considered positively identified and reported.
Results
Extraction of Cell Wall Associated Proteins
The S. aureus surface proteome was used as the target for immunoproteomics in
this study. Figure 4-1 illustrates the method of preparation of protein samples used to
promote reliable identification of immunogenic surface or cell-wall bound proteins. S.
aureus was cultured in low iron media (LIM) for the induction of virulence-related
surface/cell wall anchored proteins and collected during late exponential and early
stationary phase. Cells were trypsinized to release the cleaved surface fraction and
separated in the first dimension by iso-electro focusing (IEF). After second-dimension
separation, immunoproteomic analysis was conducted by performing a western blot on
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the 2DE gel using S. aureus infected pooled milk. The goal of these methods was to
detect surface exposed S. aureus proteins that induced humoral responses in the mastitic
milk of infected cows.
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Figure 4-1. Diagram of the immunoproteomics techniques used for detection of
immunogenic surface proteins from S. aureus. The experimental workflow, including:
2DE, immunoblots and mass spectrometry analysis, for identifying bovine disease
relevant antigens is shown.
Identification of Immunogenic Antigens
S. aureus Newbould 305, an S. aureus bovine clinical isolate, and E. coli (DH10) surface proteins were trypsinized and extracted and first run in one dimension on SDSPAGE (Figure 4-2A, lanes 1 and 2). The isolated proteins were then rehydrated and
separated on a two-dimensional gel, as shown in Figure 4-2B and D. In order to assess
the immunogenic proteins from S. aureus as previously mentioned, trypsinized proteins
were subjected to western blot. To limit the selection of cross-reactive proteins, E.coli
surface proteins were also extracted and subjected to western blot analysis using mastitic
cow milk as a negative control. As expected, mastitic milk recognized more proteins
from the S. aureus extract (Figure 4-2C). Several highly immunogenic areas (containing
multiple spots) were detected only in S. aureus blots and not in the E. coli blot (Figure 42C and E). Very few immunogenic proteins were detected in the control milk western
blots. The anti-staphylococcal antibody repertoires from mastitic cows were deemed to be
unique and a relevant tool for further analysis.
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Figure 4-2. Representative SDS-PAGE, 2DE and western blots showing the
workflow to the selection of immunogenic spots (A) The 1-dimensional SDS-PAGE
image of S. aureus Newbould 305 trypsinized protein (lane 1) and E. coli trypsinized
protein (lane 2). (B) 2DE gel conducted on 7 cm, pH 4-7, IPG strips on S. aureus
trypsinized protein. (C) Immunoblot of S. aureus 2DE using pooled bovine mastitic
milk, with the immunogenic region highlighted in red circles. (D) 2DE gel conducted
on 7 cm, pH 4-7, IPG strips on E. coli trypsinized protein. (E) Immunoblot of E. coli
2DE using bovine mastitic milk, with the immunogenic areas of the blot highlighted
in red circles.
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LC-MS/MS and in silico Analysis
2DE was performed five times, using trypsinized proteins from Newbould 305, a
clinical bovine mastitis S. aureus isolate and E. coli. The collected immunogenic spots
corresponding to western blots were picked and identified by tandem mass spectrometry.
An uninterpreted database search approach using Sequest and Mascot algorithms was
employed to identify peptides and proteins. The complete set of identified proteins using
this approach is listed in Table 4-4 and ranked by coverage, location and function. The
most promising immunogenic proteins for incorporation into a bovine vaccine were
further ranked on the basis of location and function using the PSORTb, UniProt and
Vaxign online tools (Table 4-2) [251–253]. Two specific surface exposed proteins and
virulence factors, IsdC and EsxA, were targeted for further characterization. Figure 4-3
shows a representative peptide spectral match of the isolated IsdC and EsxA 2DE
peptides.
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Table 4-2. Selected antigens on the basis of coverage, function, adhesion probability
and location.
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Figure 4-3. Representative MS/MS spectra of peptides identified by Mascot. (A)
MS/MS fragmentation of AQGEIAANWEGQAFSR found in the ESAT-6 secretion
system extracellular protein (EsxA); (B) MS/MS fragmentation of
FNGPTDVAGANAPGKDDK found in the Iron-regulated surface determinant
protein C (IsdC).
Conservation and Prevalence of Antigens
To determine if IsdC and EsxA are conserved at the amino acid level,
phylogenetic analysis was completed using 50 published sequences
(www.ncbi.nlm.nih.gov) as shown in Figure 4-4. Results include five known cow isolates
and percent identity is compared to S. aureus Newbould 305. Sequences of both proteins
are highly conserved, with EsxA 100 % conserved among S. aureus. PCR was performed
to estimate the genetic prevalence of isdC and esxA in bovine isolates of S. aureus. Genespecific primers (Table 4-1) were used to amplify the genes from 37 clinical bovine S.
aureus isolates and compared previously reported analysis of isdA [184]. As shown in

97

Table 4-3, The results indicate that the presence of isdC and esxA is 92% conserved
in bovine S. aureus isolates.

Figure 4-4. Dendrogram of pairwise amino acid alignments of (A) IsdC and (B)
EsxA from 50 published sequences. Evolutionary analysis was performed with the
Maximum Likelihood method based on the JTT matrix-based model (MEGA,
Version 7). Percent identity to the sequence from the bovine Newbould 305 S. aureus
strain is shown. Isolates from cow (*) are indicated
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Cloning, Expression and Immunogenicity of Antigens
isdC and esxA were cloned into a 6X histidine vector to construct the expression
plasmids, pNM003 and pNM002 (Figure 4-5A and C). IsdC (~25.5 kD) and EsxA (~14.5
kD) proteins were then expressed and analyzed on SDS-PAGE (Figure 4-5B and D).
Purified proteins were then used to confirm the immunogenicity of IsdC (Figure 4-6B)
and EsxA (Figure 4-6C) by ELISA using S. aureus culture positive or negative milk from
5 different cows. Immune responses to the previously characterized IsdA were also
determined for comparison (Figure 4-6A) [184]. IsdC and EsxA were found to stimulate
significant IgG antibody titers in mastitic milk as compared to uninfected milk. Results
indicate that IsdC and EsxA are immunogenic and expressed in vivo in the bovine udder.
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Figure 4-5. Expression and purification of IsdC and EsxA proteins. (A) Structure
and operon organization of pNM003 for His-IsdC expression and (B) SDS-PAGE of
purified IsdC (~25.5 kDa). (C) Structure and operon organization of pNM002 for HisEsxA expression and (D) SDS-PAGE of purified EsxA (~14.5 kDa). E1= elution 1, E2
= elution 2.
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Figure 4-6. Antigen-specific IgG responses from S. aureus culture positive and S.
aureus culture negative bovine milk. (A) anti-IsdA, (B) anti-IsdC, and (C) anti-EsxA
IgG responses. Data are presented as the log transformed geometric mean of
independent titers from five cows. Significance (*) of anti-IsdA (p=0.014), anti-IsdC
(p=0.035) and EsxA (p=0.019) using a two-tailed Student’s t-test for unequal variance.
Discussion
Bacterial surface proteins are critical immunodominant antigens that are often the
first molecules to interact with host cells and tissues. These proteins are especially
important targets for S. aureus vaccine development as they are also key for adhesion and
nutrient acquisition, and their presence and structure more conserved across strains than
the polysaccharide capsule [254]. In this study, our approach was to identify
immunogenic cell wall associated and surface proteins for characterization as vaccine
antigens to prevent S. aureus bovine mastitis. The presence of anti-staphylococcal IgG
antibodies in milk during subclinical and clinical bovine mastitis has been reported [92].
Here, we report a unique immunoproteomics strategy to detect antigenic staphylococcal
proteins using IgG present in milk. A total of 38 unique and immunogenic S. aureus
proteins were identified, out of which 17 proteins were cell wall associated, or
extracellular, and previously reported as involved in virulence. Eight proteins were
further ranked based upon their subcellular location, coverage and function and two of
them, IsdC and EsxA, purified for confirmation of immune responses [21].
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Despite taking precautions to minimize cell lysis, this approach did also identify
intracellular or cytosolic proteins including: elongation factors and ribosomal proteins
(Supplementary Table 1). Adjustment of trypsinization time and conditions did not
eliminate the presence of these proteins, and the detection of cytosolic proteins is a
recognized limitation of immunoproteomics [255]. While immunogenic cytosolic
proteins can be potential vaccine antigens, they may also be detected due to abundance,
and thus we did not pursue the characterization of them [256]. Phase of growth is also a
key consideration for immunoproteomics. We targeted the late exponential phase and
early stationary phases of growth (0.75-1.2 OD600 in LIM) as previous reports, and our
studies, have indicated this range is optimal for isdA and other virulence factor
expression [257]. IsdA is a well characterized immunogenic surface adhesin from S.
aureus, and we, unexpectedly, did not identify this protein using these techniques [258].
Lack of identification of IsdA could be due to trypsinization methods that result in
aberrant IsdA cleavage, lack of release of IsdA due to surface hydrophobicity, or low
peptide concentration that was not detected or not fully resolved from other spots/proteins
[259]. We attempted to isolate surface proteins using alternate techniques, including:
lysostaphin and silica beads (data not shown), but these efforts resulted in the
identification of many more cytosolic proteins. Trypsinization enables extraction of
surface proteins effectively but is limited to exposed lysine and arginine amino acid
residues on the surface. Despite these limitations, a number of immunogenic S. aureus
virulence factors that may represent bovine vaccine candidates were identified, and
results emphasize the significance of milk antibodies for the identification of antigens
exposed during udder colonization and mastitis.
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Out of the top eight identified proteins, IsdC and EsxA were selected for further
analysis on the basis of coverage by mass spectrometry, cell wall location and function in
relation to virulence and pathogenesis. IsdC and EsxA were tested for reactivity to bovine
milk from S. aureus infected cows as an indicator of surface exposure in vivo. In
comparison to the IsdA antigen, which has been reported to induce antibody production
during S. aureus mastitis, EsxA and IsdC were also immunogenic [184]. These proteins
have been studied and described as virulence factors for S. aureus pathogenesis. EsxA is
a surface exposed S. aureus protein as determined by trypsinization and mass
spectrometry [260]. This protein is also an important factor for pathogenesis and abscess
formation in mice [261]. A recent report identified anti-EsxA antibodies in patients
infected with antibiotic resistant strains of S. aureus [81]. EsxA has also been evaluated
as a vaccine candidate, and induces Th1 and Th17 immune responses against invasive S.
aureus in murine models [82,262]. IsdC is a surface adhesin from the Isd (iron regulated
surface determinant) family that is required for iron sequestration and ECM binding. IsdC
is involved in haem transfer from the membrane to the cytosol and important, but not
essential, for S. aureus iron uptake [263]. IsdC contains one near-iron-transporter
(NEAT) domain similar to IsdA, and may contribute to biofilm formation through
dimerization [84]. In this study, we found both IsdC and EsxA to be highly conserved at
the amino acid level using published genomes, and isdC and esxA were present in 92% of
tested bovine S. aureus isolates.
Other proteins identified using this technique also represent interesting vaccine
candidates, including: FeoB, Map, SpA and IsaA [248,264–268]. These proteins were not
currently selected for further analysis due to significantly lower coverage by mass
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spectrometry. However, a number of them have been pursued as human vaccine
candidates and may also represent bovine candidates. While additional studies are
required to assess the specific immunogenicity and protective efficacy of IsdC and EsxA
in bovines, the methods described here are unique and represent a useful screen to
identify bovine mastitis vaccine candidates.

Table 4-4. S. aureus proteins identified as ranked by mass spectrometry coverage
Accession No.

Protein name

Symbol

Coverage

# AAs

Function

Location

Transmembrane
helices

Q99WU4

ESAT-6 secretion system

ESXA

89.69

97

Virulence factor

Extracellular

0

AHPC

40.21

189

Peroxidase activity

Cytoplasm

0

extracellular protein A
Q2FJN4

Alkyl hydroperoxide reductase
subunit C

A7X3V3

UPF0342 protein SAHV_1830

Y1830

32.46

114

unknown

Cytoplasm

0

A6U0U8

Iron-regulated surface

ISDC

29.07

227

Hemoglobin binding/metal

Cell wall, extra

2

ion binding

cellular

Structural constituent of

Cytoplasm

0

determinant protein C
Q2FEQ7

50S ribosomal protein L30

RL30

23.73

59

ribosome
Q5HG56

Probable tautomerase

Y1399

19.67

61

Isomerase activity

Cytoplasm

0

SPA

18.80

516

IgG binding

Cell wall

1

ISAA

15.02

233

Hydrolase activity, acting on

Extracellular

0

Cytoplasm

0

Cytoplasm

0

SACOL1399
P02976

Immunoglobulin G-binding
protein A

P60157

Probable transglucosylase IsaA

glycosyl bonds
P99075

Fructose-bisphosphate

ALF2

9.79

286

aldolase
A6U135

Methionyl-tRNA formyl
transferase

Fructose-bisphosphate
aldolase activity

FMT

8.68

311

Methionyl-tRNA formyl
transferase activity

104
A6U174

30S ribosomal protein S2

RS2

8.24

255

Structural constituent of

Cytoplasm

0

ribosome
P0AEZ5

Septum site-determining

MIND

7.04

270

ATPase activity

Cell membrane

0

CAPB

4.82

228

ATP binding

Cytoplasmic

0

protein MinD
P39851

Putative tyrosine-protein
kinase CapB

P66816

NAD-dependent protein

Membrane
NPD

4.53

243

Metal ion binding

Cytoplasm

0

deacetylase
Q6GI27

Protein FmtA

FMTA

4.28

397

Antibiotic resistance

Cell membrane

1

P63582

Arginosuccinate lyase

ARLY

4.14

459

Arginosuccinate lyase

Cytoplasm

0

Cell inner

2

activity
P35272

Chain length determinant

WZZB3

4.00

325

unknown

protein
Q8FB30

tRNA-dihydrouridine

membrane;
DUSA

3.93

331

Flavin adenine dinucleotide

Cytoplasm

0

binding
P37386

Probable cadmium-

CADA2

3.86

804

ATP binding

Cell membrane

7

Y1799

3.81

578

ATPase activity, coupled to

Cell membrane

5

transporting ATPase
Q2YU20

Q2YUG0

Putative multidrug export ATPbinding/permease protein

transmembrane movement

SAB1799c

of substances

tRNA N6-adenosine threonyl

TSAD

3.52

341

metal ion binding

Cytoplasmic

0

carbamoyl transferase
Q6G845

UPF0421 protein SAS1811

Y1811

3.35

328

unknown

Cell membrane

4

Q2FVZ4

Lipid II: glycine

FEMX

3.33

421

Transferase activity,

Cytoplasm

0

glycyltransferase

transferring amino-acyl
groups

P58995

dITP/XTP pyrophosphatase

IXTPA

3.08

195

metal ion binding

Cytoplasm

0

Q5HD01

Fe (Ferrous iron transport

FEOB

3.01

664

Ferrous iron

Cell membrane

10

Cell membrane

0

protein B)

transmembrane transporter
activity

Q5HE97

ATP synthase subunit beta

ATPB

2.98

470

ATP binding

105
Q2FWE3

Low molecular weight protein-

PTPB

2.88

139

tyrosine-phosphatase PtpB
P21224

Uncharacterized leukocidin-

Protein tyrosine

Cytoplasm

0

phosphatase activity
LUKL1

2.66

338

Pathogenesis

Extracellular

0

ATL

2

1248

Amidase activity

Cell wall

0

PYRE

1.97

203

Orotate phosphoribosyl

Cytoplasm

0

Cell membrane

2

Extracellular/

1

like protein 1
Q99V41

Bifunctional autolysin
[Includes: N-acetylmuramyl-Lalanine amidase

Q5HGM7

Orotate phosphoribosyl
transferase

P72367

Capsular polysaccharide type 8

transferase activity
CAP8A

1.80

222

biosynthesis protein cap8A
Q6GDD3

Lipase 1

Sugar efflux transmembrane
transporter activity

LIP1

1.62

680

Metal ion binding

membrane
A6U074

ATP-dependent

ADDA

1.56

1217

ATP binding

Cytoplasm

0

ILVE

1.40

358

L-isoleucine transaminase

Cytoplasm

0

helicase/nuclease subunit A
Q6GBT3

Probable branched-chainamino-acid aminotransferase

activity

Q69HT9

Multicopper oxidase

MCO

1.34

447

Copper ion binding

Cytoplasm

0

Q5HG29

Conserved virulence factor B

CVFB

1.33

300

unknown

Cell membrane

0

Q6GGU4

3-dehydroquinate synthase

AROB

1.13

354

3-dehydroquinate synthase

Cytoplasm

0

5(carboxyamino)imidazole

Cytoplasmic

0

ribonucleotide synthase

Membrane

activity
Q7A695

N5-carboxyaminoimidazole
ribonucleotide synthase

PURK

1.07

374

activity

105

CONCLUSIONS AND INTERPRETATIONS
The chapters of this work focus on evaluating various aspects of designing a
mucosal vaccine against S. aureus mastitis. We hypothesized that a mucosal, enterotoxinbased vaccine containing multiple relevant antigens will protect cows against S. aureus
mastitis. To being to address this hypothesis and construct a vaccine for bovine mastitis,
experimentation focused on three main areas: 1) characterizing the IsdA antigen for its
intra-strain conservation, ECM binding, and immune reactivity for use as a bovine
vaccine candidate, 2) analyzing the immunogenicity and safety of a cholera toxin based
subunit vaccine (IsdA-CTA2/B + ClfA-CTA2/B), and 3) developing an
immunoproteomics approach to discover new proteins from S. aureus that can be
incorporated into the vaccine. As discussed in Chapter 1, deteriorating animal health and
economic losses caused by bovine mastitis is a worldwide concern. S. aureus caused
mastitis is of critical importance due to refractory antibiotic treatments and the growing
incidence of antibiotic resistance. Additionally, the contagious nature of S. aureus caused
mastitis and ability to establish subclinical infection make prevention of this disease a top
priority. An effective vaccine against this pathogen that can prevent mastitis caused by
different strains and serotypes will reduce the use of antibiotics, improve animal health,
reduce economic losses and also provide valuable information for human S. aureus
vaccine development.
IsdA has been previously described as an important vaccine antigen and is also
used in potential human vaccines with other antigens. However, the characterization of
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IsdA specifically as a bovine antigen has not been reported and is explored here for the
first time. It is known that, due to intra-strain variability, the conservation of antigens is
critically important for a vaccine against a pathogen like S. aureus. As discussed in
Chapter 2, a main focus of this research was to identify the genetic prevalence and
expression of IsdA from bovine S. aureus. Our results indicate that IsdA is present in 28
strains from a total of 29, making it 97% percent conserved (Table 2-2, Chapter 2). In
addition to IsdA we also detected prevalence of a number of other surface adhesins from
S. aureus (Table 2-2, Chapter 2). Immunogenicity assays from this study revealed that the
IsdA antigen can stimulate antigen-specific active antibodies that were capable of
opsonophagocytosis, supporting the conclusion that IsdA is a promising bovine vaccine
antigen. Multiple alignment of the IsdA protein revealed the presence of two different
variants of IsdA (represented by strains Newbould 305 and MRSA252). Four amino acid
differences observed at the C-terminal of these two variants of IsdA mediated variable
binding preferences to the host ECM molecules FN and FG (Figure 2-2, Chapter 2). The
NEAT domain of IsdA is known to coordinate FG binding, however, the role of the Cterminal in ECM binding was identified in this study for the first time.
The studies described in Chapter 2 determined that IsdA is expressed in milk in
vivo during active S. aureus infection. To detect the level of expression of isdA and other
antigens in vitro we performed additional qRT-PCR analysis of isdA, clfA, isdB and flbA
under the iron limiting conditions of milk using S. aureus (Newbould 305), S. aureus
(MRSA USA300) and S. haemolyticus. These results revealed that there is increased
expression of isdA, isdB and clfA in the iron limiting conditions of milk from S. aureus
(305 Newbould) and S. aureus (MRSA), but not S. haemolyticus. Although the
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expression was increased for all three adhesins, isdA and isdB showed higher expression
than clfA (Appendix A, Figure A-1). Furthermore, we conducted growth curve analysis
on all the three strains, to detect if the change in expression in milk is solely due to
growth phase changes, and the results indicated partial interdependence of expression on
growth phase as well as iron limitation (Figure A-2, Appendix A). In addition, we
identified enhanced binding of bovine strains of S. aureus (305, Newbould) to FN in milk
as compared to LB (Figure A-3, Appendix A).
The data presented in Chapter 2 and Appendix A highlight that IsdA is an
important surface adhesin for S. aureus and a promising candidate for bovine vaccines.
Although IsdA is likely to be highly conserved, future studies with a larger number of
strains, from different geographical regions, will be important, for better characterization
of this antigen. Also, additional in vitro gene expression studies in low iron conditions of
milk with immunogenic proteins (IsdC, EsxA and SpA) will be valuable to understand
their roles in bovine mastitis. The ECM binding assays of our study, revealed higher
binding of bovine strains to FN in the presence of milk, however, binding with other
ECM molecules like laminin and collagen IV should be evaluated, as these molecules are
also abundant in bovine udder and are involved in mammary gland development. Lastly,
creating a isdA targeted gene mutant to study the pathogenicity and ECM binding of this
antigen in vitro and in vivo might be the gold standard, however, redundancy of S. aureus
adhesins have in the past been shown to be a problem for analysis in mutational studies.
As discussed in Chapter 3, two field trials on the mucosal subunit vaccine
containing IsdA and ClfA (IsdA-CTA2/B and ClfA-CTA2/B) were conducted. The trails
differed in the amount of vaccine administered and the number of booster doses
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thereafter. Results indicate that the stimulation of significant immune responses occurred
in vaccinated animals and a slight but effective booster response occurred that produced
antibody responses prior to freshening. Trial 2 in these studies had a higher dosage of
vaccine from the start which contributed to higher immune responses throughout the 50day vaccination trial period. IsdA and ClfA were able to induce antigen-specific
antibodies, however, IsdA consistently showed higher and more significant immune
responses. The vaccine induced significant humoral and cellular immune responses in
serum, and while significance responses in milk were not detected by ELISA, data
supportive. Increased expression of IL-4 cytokines was determined on day 60 of Trial 2,
indicating that this vaccine induces aTh2 bias. Importantly, serum and milk antibodies
stimulated by the vaccine were able to successfully induce opsonophagocytosis (Figure
3-3 and 3-4, Chapter 3). These results provide evidence that induced antibodies were
active and specific to the antigen, which is key for a successful S. aureus vaccine.
Antibodies stimulated in milk could also significantly induce opsonophagocytosis,
despite being non- significant in ELISA immune assays, indicating that these important
antibodies are also present and efficient in inducing bacterial killing (Figure 3-7, Chapter
3). Overall results from immunogenicity trials show that the vaccine is inducing effective
immune responses, however the immune stimulation was lower in milk, indicating that
there is a requirement for more exploration of additional antigens and the mechanisms
involved. The intranasal route showed promising results, although other methods like
intramammary or intravaginal routes of delivery might also be explored in the future. A
challenge trial for this vaccine is underway, and although these studies are technically
difficult, it might provide valuable information about the protective capabilities of the
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vaccine. Further, a field trial with a larger number of cows and with newer immunogenic
antigens will be important to detect the enhancement of the effectiveness of the
multivalent vaccine. In addition, more knowledge on the critical role of specific antigen
during mastitis can be evaluated on mastitic mouse models.
The mucosal vaccine analyzed in Chapter 3, was comprised of two antigens, and
we aim to incorporate new antigens into this vaccine in the future. To identify new
immunogenic proteins from the surface of S. aureus, we developed an
immunoproteomics based approach as described in Chapter 4. This unique approach
allowed us to detect immunogenic proteins from the surface of S. aureus by using milk
antibodies (Figures 4-1, 4-2 and 4-3, Chapter 4). Two-dimensional electrophoresis
coupled with western blotting and mass spectrometry, led to the identification of 54
proteins from S. aureus and 8 unique immunogenic surface proteins involved in
virulence. Two of the eight proteins, IsdC and EsxA, showed high immunogenic potential
and, with further characterization, can be incorporated into the vaccine (Figure 4-6,
Chapter 4). Further analysis on 6 of the identified 8 surface proteins is underway through
cloning and protein purification. After this characterization, these antigens can be
potentially incorporated into the mucosal S. aureus vaccine. Although this technique
enabled us to discover new antigens, few well-known immunogenic antigens like IsdB,
ClfA, and FnbpA, were identified in these experiments, which suggests a limitation. This
technique strongly relies on the capability of trypsin to shave off the surface proteins,
which means cleaving only on lysine and arginine residues. Thus, important
immunogenic proteins may have been missed. Future work for this aim may include the
extraction of surface proteins from S. aureus under more stringent conditions of digestion

110
time, growth phase and concentration of trypsin to ensure less contamination of cytosolic
proteins, and may also include the use of other enzymes like elastase and proteinase K for
surface protein extraction by S. aureus.
The innovation and unique activity of this bovine S. aureus mucosal vaccine lies
in its purified and multivalent nature, and its combination with a cholera toxin-based
adjuvant. Cholera toxin adjuvant is a well-known and potent immunomodulator, that aids
in antigen presentation, B cell isotype switching and translocation of co-administered
antigens. This adjuvant, in combination with S. aureus surface proteins that are key
targets for blockage, has the capacity to prevent bacterial colonization. While the
protective efficacy of this vaccine is yet to be determined, the experiments described are
essential steps in its progress and development, and these studies suggest it has the
potential to improve animal health by preventing bovine mastitis caused by S. aureus. An
effective vaccine would have positive impacts on milk production, antibiotic use, and
agricultural economics and may also have lasting positive effects on human health and
nutrition.
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APPENDIX A
The Low Iron Conditions of Milk Promote Staphylococcus Aureus IsdA Expression
and Fibronectin Binding
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Materials and Methods
Bacterial growth, RNA isolation and quantitative real-time PCR.
S. aureus Newbould 305, S. aureus USA 300 and S. haemolyticus (bovine, isdA+)
were grown in Luria Broth (LB) to a bacterial count of 1x 108 cells. Cultures were
harvested and grown microaerophilically in 5% skim milk (SKM), SKM + 200 M
FeSO4, LB or Low Iron Media (LIM: 2 g NaCl, 1.2 g NaHCO3, 1.6 g yeast extract, 6 g
protease peptone to 400 mL) at 37°C (21). Optical density was determined at 600 nm
every 4 hours. At 12 hr and 24 hr, cultures were centrifuged at 3000 Xg and the pellet
was washed 2X in buffer (1X PBS + 0.5 mM EDTA). Total RNA was extracted from the
cell pellet as described above for RT-PCR. RNA was suspended in 30 μl RNase free
water and then stored at -80°C. RNA concentration and purity was confirmed by the
260/280 ratio (Nanodrop, Thermo-Fisher) and PCR reactions were conducted between
each step to ensure the absence of genomic DNA. Total isolated RNA was used to
synthesize first strand cDNA according to manufacturer’s instructions (Revert Aid Kit,
Thermo-Fisher). Resulting cDNA was diluted 1:500 with RNase free water prior to qRTPCR. The qRT-PCR was conducted using SYBR FAST qPCR master mix (Kappa
Biosystems, Wilmington, MA). All samples were assayed using standard cycling
conditions of: denaturation at 95 °C for 3 min and 40 amplification cycles of 95 °C for 15
sec, 60 °C for 30 sec and 72 °C for 30 sec (Eppendorf Mastercycler Realplex2 ). All
reactions contained 2 μl of cDNA template, 10 μl of SYBR Green Master Mix (2X), 0.5
μl of 100 μM of each primer, and 7 μl of RNase free water. Fold changes were calculated
using ΔΔCT method keeping 16S as normalizer. 16S RNA was the most stable
housekeeping gene in our experiments. All the experiments were conducted with three
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biological replicates repeated at least three times.
Fibronectin binding assays.
Black walled and clear walled (Nunc, Thermo-Fisher) ninety-six well plates were
coated with 50 µl of 10 µg/mL fibronectin (R&D Systems, Minneapolis, MN) in 1x PBS,
and incubated for 12 hr at 4°C, followed by two washes of 100 l in 1X PBS. Plates were
then incubated at 37°C with 1x108 cells of S. aureus Newbould 305, S. aureus USA300,
or S. haemolyticus (isdA+) in either LB versus SKM, or SKM versus SKM + 200 M
FeSO4 for 12 hours. After incubation, the plates were washed with 100 l of 1X PBS two
times and 150 μl Alamar Blue dye (0.1% reazzurin in 1X PBS) was added to black
walled plates for the fluorescent metabolic dye assay. Plates were read at 530/590 nm
after 12, 18 and 24 hrs. Assays were also performed by adding 100 l of top agar (10 g
LB, 3 g agar to total 400 mL) to clear walled plates instead of Alamar Blue. Bacterial
growth was quantified by the absorbance of top agar plates read at 600 nm after 12 and
24 hrs at 37°C. For serum-blocking, assays were performed as described above, however
1:100 dilution of heat inactivated immunized and mock immunized (1X PBS) mouse
serum was mixed with 1x108 cells of S. aureus MRSA252 that had been grown overnight
in LIM. The mixture was incubated at 37°C for 30 mins and 100 L was added to the
ninety-six well plates containing 10 ug/mL fibronectin in 2-fold dilutions. Plates were
washed and quantified with Alamar Blue as described. Pooled, day 14 anti-IsdA mouse
serum was obtained after intranasal vaccination of 6 9-week old BALB/c mice that
received purified IsdA (17 g) plus CT (5 g) adjuvant on days 0 and 10, as described
previously (22).
Graphing and statistical analysis.
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All graphing and statistical analysis was performed with JMP SAS software
(Cary, NC) or R version 3863.0.2. PCRs, ELISAs and CFU assays were performed in
triplicate. The ΔΔCT method was used to calculate fold changes for qPCR experiments.
Significance was calculated using Tukey-Kramer pairwise comparison on JMP software
using three biological and two test replicates. Significance between antibody responses,
SCC and CFU counts were determined using the non-parametric Wilcoxon Rank Score
(Mann-Whitney) test or between three groups using the Tukey-Kramer pairwise
comparison. P-values are reported as p < 0.05(*) or p < 0.01(**) with a value of p <0.05
considered statistically significant.
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Figure A-1. Expression of staphylococcal adhesins in vitro. Quantitative RT-PCR
showing normalized Ct values as fold change comparison of gene expression after
growth of human and bovine Staphylococcus in A) 5% skim milk (SKM) compared
to Luria broth (LB), B) low iron media (LIM) compared to LB and C) SKM plus
FeSO4 compared to SKM alone, after 24 hours at 37C. Significance using the TukeyKramer pairwise comparison, p ≤ 0.05(*), p ≤ 0.01(**), p ≤ 0.001 (***) or p ≤ 0.0001
(****) between the expression of genes is shown.
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Figure A-2. Growth curves of human and bovine staphylococcal isolates Colony
forming units (CFU/mL) of A) bovine S. aureus Newbould 305, B) human S. aureus
USA300 and C) bovine S. haemolyticus grown in vitro for 28 hours in LB (green),
SKM (red) and LIM (blue).
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Figure A-3. Binding of human and bovine staphylococcal isolates to fibronectin.
Fibronectin-binding as determined by metabolic dye assay of S. aureus Newbould
305, S. aureus USA300 and S. haemolyticus after growth in A) SKM versus LB and
B) SKM versus SKM +FeSO4. Significance using the Student’s T-test, p ≤ 0.05(*), p
≤ 0.01(**) or p ≤ 0.001 (***), between fibronectin binding after growth in different
media is shown.
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Figure A-4. Quantitative RT-PCR of adhesin expression from bovine S. aureus
Novel Cow (NC) Normalized Ct values as fold change comparison of gene expression
are shown after growth of NC in A) 5% skim milk (SKM) compared to Luria broth
(LB), B) low iron media (LIM) compared to LB and C) SKM plus FeSO 4 compared
to SKM alone, after 24 hours at 37C. D) Growth curve in CFU/mL of NC growth LB
(green), SKM (red) and LIM (blue). Significance using the Tukey-Kramer pairwise
comparison, p ≤ 0.05(*), p ≤ 0.01(**), p ≤ 0.001 (***) or p ≤ 0.0001 (****) between
the expression of genes is shown.

